Depth of consciousness monitor

Description

FIELD OF THE DISCLOSURE

The present disclosure relates to the field of patient monitoring. In some embodiments, the disclosure relates to monitoring the depth of consciousness of a patient under anesthetic sedation.

BACKGROUND

General anesthesia is often used to put patients to sleep and block pain and memory during medical or diagnostic procedures. While extremely useful, general anesthesia is not risk free. Caregivers therefore generally seek to maintain a depth of consciousness consistent with the needs of a particular medical procedure. Caregivers will monitor various physiological parameters of the patient to predict the patient's depth of consciousness. In response to monitored parameters, the caregiver may manually adjust the anesthetic dosage level to avoid over and under dosing. However, as a patient's depth of consciousness may frequently change, caregivers often employ a host of monitoring technologies to attempt to periodically, sporadically, or continually ascertain the wellness and consciousness of a patient. For example, caregivers may desire to monitor one or more of a patient's temperature, electroencephalogram or EEG, brain oxygen saturation, stimulus response, electromyography or EMG, respiration, body oxygen saturation or other blood analytes, pulse, hydration, blood pressure, perfusion, or other parameters or combinations of parameters. For many of the foregoing, monitoring technologies are individually readily available and widely used, such as, for example, pulse oximeters, vital signs monitors, and the like.

In their depth of consciousness monitoring, caregivers may also use recording devices to acquire EEG signals. For example, caregivers place electrodes on the skin of the forehead to detect electrical activity produced by the firing of neurons within the brain. From patterns in the electrical activity, caregivers attempt to determine, among other things, the state of consciousness of the brain. Caregivers may also use a pulse oximeter or cerebral oximetry to determine the percentage of oxygenation of the hemoglobin in the patient's blood. Caregivers may also use an EMG monitor to detect the muscular action and mechanical impulses generated by the musculature around the patient's forehead, among other bodily locations. Caregivers manually monitor such physiological parameters and then manually adjust anesthetic dosage.

However, manual monitoring and dosage adjustment could lead to serious adverse results, including death, if improperly performed. In addition, typical depth of consciousness monitors do not account for variations in responses to sedation therapies that exist between patient demographics. Furthermore, typical depth of consciousness monitors do not account for differences in physiological responses that exists between particular sedation therapies and among different patient populations. Therefore, there remains a need in the art for a depth of consciousness monitor that is configured to automatically communicate with a caregiver and/or an anesthetic dosage device to provide accurate control over patient care by accounting for variations between populations and drug actions.

SUMMARY

Based on at least the foregoing, the present disclosure seeks to overcome some or all of the drawbacks discussed above and provide additional advantages over prior technologies. The present disclosure describes embodiments of noninvasive methods, devices, and systems for monitoring depth of consciousness through brain electrical activity.

In one embodiment, a depth of consciousness monitor is configured to determine the level of sedation of a medical patient. The depth of consciousness monitor includes: an EEG interface configured to receive an EEG signal from an EEG sensor; an EEG front end configured to pre-process the EEG signal; a processor, configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal, wherein the processor is further configured to determine delay information associated with the time the EEG signal is received and the time the level of sedation is determined; and a drug delivery device interface, configured to provide the level of sedation and the delay information to a drug delivery device.

In some embodiments the EEG front end includes an EEG engine and an EMG engine configured to extract EEG information and EMG information from the EEG signal, respectively. In some embodiments, the processor is further configured to time stamp the EEG signal when received from the EEG sensor. In one embodiment, the depth of consciousness monitor also includes an additional sensor front end, such as an SpO2 sensor front end. In some embodiments, the depth of consciousness monitor also includes a data port configured to receive at least one of patient data and drug profile information. The processor may be configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal and the at least one of patient data and drug profile information. In some embodiments, the depth of consciousness monitor also includes the EEG sensor and/or the drug delivery system. In some embodiments, the drug delivery device interface includes a wireless communication device.

In another embodiment, a depth of consciousness monitor is configured to determine the level of sedation of a medical patient. The depth of consciousness monitor includes: an EEG interface configured to receive an EEG signal from an EEG sensor; an EEG front end configured to pre-process the EEG signal; a processor, configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal, and a data port configured to transmit the patient sedation level. The processor can include: two or more computing engines, each configured to compute a possible sedation level according to a different process; and a decision logic module, configured to determine the patient's sedation level based at least upon the possible sedation level computations;

In some embodiments, at least one of the computing engines is configured to implement a motion vector process, a phase coherence process, and/or utilize a brain model to compute one of the possible sedation levels. The EEG front end may include an EEG engine and an EMG engine configured to extract EEG information and EMG information from the EEG signal, respectively. In some embodiments, the data port comprises a display and/or a wireless communication device.

In yet another embodiment, a method of determining the level of sedation of a medical patient is provided. The method includes: receiving an EEG signal indicative of a medical patient's EEG; receiving treatment data associated with at least one of the medical patient and a drug to be delivered to the medical patient; and determining a level of sedation based at least upon the EEG signal and the treatment data.

In some embodiments, the treatment data includes at least one of a patient age, age classification, sex, weight, body-mass index, a physiological parameters, a temperature, a blood oxygen concentration, an EMG signal, a drug type, a drug class, a mechanism of delivery, and an active ingredient. In some embodiments, determining a level of sedation comprises determining two or more possible levels of sedation with parallel computing engines and wherein said determining the level of sedation of the medical patient is based upon said possible levels of sedation. In some embodiments, determining the level of sedation comprises averaging two or more possible levels of sedation and/or selecting one of the possible levels of sedation as the level of sedation of the medical patient. In some embodiments, determining the possible levels of sedation is performed with motion vector analysis, phase coherence, and or by utilizing a brain model.

For purposes of summarizing the disclosure, certain aspects, advantages and novel features of the disclosure have been described herein. Of course, it is to be understood that not necessarily all such aspects, advantages or features will be embodied in any particular embodiment of the disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings and the associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims.

FIG. 1 illustrates an embodiment of a depth of consciousness monitoring system under closed-loop control.

FIG. 2 illustrates a block diagram of one embodiment of the depth of consciousness monitor of FIG. 1.

FIG. 3 illustrates one embodiment of the forehead sensor of FIG. 1.

FIG. 4 illustrates one embodiment of an EEG frequency spectrum of the patient before and during sedation using the depth of consciousness monitor of FIG. 2.

FIG. 5 illustrates one embodiment of the processor of the depth of consciousness monitor of FIG. 2.

FIG. 6 illustrates another embodiment of the processor of the depth of consciousness monitor of FIG. 2.

FIG. 7 illustrates yet another embodiment of the processor of the depth of consciousness monitor of FIG. 2.

FIG. 8 illustrates one embodiment of a routine to determine patient sedation information that can be performed by any of the processors of FIGS. 5-7.

FIG. 9 illustrates another embodiment of a routine to determine patient sedation information that can be performed by any of the processors of FIGS. 5-7.

FIG. 10 illustrates another embodiment of a depth of consciousness monitoring system.

FIG. 11 illustrates one embodiment of the depth of consciousness monitoring system of FIG. 10.

FIG. 12 illustrates one embodiment of the depth of consciousness monitoring assembly of FIG. 10.

FIG. 13 illustrates the depth of consciousness monitoring assembly of FIG. 12 attached to a sensor assembly.

FIGS. 14-16 illustrate views of the display of a multi-parameter monitor displaying physiological signals received from the depth of consciousness monitor of FIG. 10.

DETAILED DESCRIPTION

The present disclosure generally relates to patient monitoring devices. In order to provide a complete and accurate assessment of the state of a patient's various physiological systems, in an embodiment, a sensor may advantageously monitor one, multiple or combinations of EEG, EMG, cerebral oximetry, temperature, pulse oximetry, respiration, and other physiological parameters. In various embodiments, the sensor includes a disposable portion and reusable portion. For example, the disposable portion may advantageously include components near a measurement site surface (the patient's skin), including, for example, an EEG sensor, an EMG sensor, a temperature sensor, tape, adhesive elements, positioning elements, or the like. In addition, or alternatively, the reusable portion may advantageously include other components, circuitry or electronics, which, in some embodiments include time-of-use restrictions for quality control or the like. The reusable portion, can be used multiple times for a single patient, across different patients, or the like, often depending upon the effectiveness of sterilization procedures. The reusable components may include, for example, cerebral oximetry components, pulse oximetry components and other components to measure other various parameters.

In an embodiment, the disposable portion of the sensor may include an inductance connection or other electrical connection to the reusable portion of the sensor. The physiological signals from all sensors can be transmitted through a common cable to a depth of consciousness monitor. In an embodiment, the depth of consciousness monitor may include an analog to digital converter, various electrical filters, and a microcontroller for processing and controlling the various sensor components.

In an embodiment, a depth of consciousness monitor is configured to communicate with the forehead sensor and one or more host display and patient monitoring stations. In an embodiment, the patient monitoring station may be a pulse oximeter. In an embodiment, the pulse oximeter may perform integrated display, data monitoring and processing of patient parameters including a connection for power and data communication. In an embodiment, some or all communication may be through wired, wireless, or other electrical connections. In an embodiment, the depth of consciousness monitor may advantageously be housed in a portable housing. In such embodiments, the unit may advantageously be physically associated with a monitored patient, such as, for example, attached in an arm band, a patient bed pouch, a hood or hat, a pocket of a shirt, gown, or other clothing, or the like. In other embodiments, the unit may be entirely or partially housed in a cable connector. In an embodiment, the signal processing and condition unit and/or the depth of consciousness monitor could also monitor patient parameters through other sensors including, for example, ECG, Sp02 from the earlobe, finger, forehead or other locations, blood pressure, respiration through acoustic or other monitoring technologies, or other clinically relevant physiological parameters.

In an embodiment, the depth of consciousness monitor communicates with a sensor, such as a forehead sensor including one or more light sources configured to emit light at a patient's forehead. In an embodiment, the light source may include one or more emitters or emitter systems, such emitters or emitter systems may be embedded into a substrate. In various embodiments, the emitters could include light emitting diodes (“LEDs”), lasers, superluminescent LEDs or some other light emitting components. These components could be arranged in any pattern on the substrate and could be either a single light emitting source or several light emitting sources. In an embodiment, the emitting components could emit light that deflects off of reflective surfaces associated with a cap of the substrate. The reflective cover could be any number of shapes or sizes and could be constructed to direct light to specific points or a point on the cap or substrate.

In an embodiment, a multi-faceted splitting mirror could reflect light to an opening in the substrate that would allow the light to escape and be emitted to an emission detector in an embodiment also housed in the light source substrate. The emission detector may advantageously sample the light providing feedback usable to create an optical bench or at least optical bench properties of the light source, including, for example, determinations of intensity, wavelength, or the like. In an embodiment, the light source may include a polarized filter for adjusting the emitter light, in some embodiments before exiting an opening in the emitter or being detected by the emission detector.

In an embodiment, a caregiver could analyze physiological information collected from the various sensors including a patient's temperature, EEG, brain oxygen saturation, stimulus response, electromyography or EMG, respiration using acoustic sensor applied to the through, body oxygen saturation, glucose concentration, or other blood analytes, pulse, hydration, blood pressure, perfusion, or other parameters or combinations of parameters to determine relevant information about the state of a patient's well-being. In another embodiment, a caregiver may advantageously analyze information collected from the various sensors to more completely assess the overall depth of a patient's sedation and obtain an assessment superior to an assessment derived from monitoring a single or a few of the parameters mentioned above.

Reference will now be made to the Figures to discuss embodiments of the present disclosure.

FIG. 1 illustrates one example of a depth of consciousness monitoring system 100. In certain embodiments, the depth of consciousness monitoring system 100 measures one or more physiological parameters including cerebral electrical activity (e.g., via EEG), cerebral muscular activity (e.g., via EMG), temperature, cerebral oxygenation, including venous and arterial oxygenation, arterial oxygenation at various other points on the body, various other blood analytes, including total hemoglobin, glucose, lipids, stimulus response, electromyography or EMG, respiration, pulse, hydration, blood pressure, perfusion, or other parameters or combination of other physiologically relevant patient characteristics. The information from these physiological parameters can be evaluated using trend analysis, absolute and relative measures of certain parameters, combined or alone to evaluate the total wellness and current state of sedation of a patient.

The depth of consciousness monitoring system 100 includes multiple or a single sensor 120 in communication with a depth of consciousness monitor 140 via a communications link 150. In the illustrated embodiment, the depth of consciousness monitoring system 100 also includes a drug delivery device 160 that receives a control signal from the depth of consciousness monitor 140 via a control link 170. The drug delivery device 160 provides one or more sedatives (e.g., narcotic, hypnotic, analgesic, opiate, etc.) to a patient 180 via a conduit 190.

The sensor 120 can include any variety of shapes and sizes, and could be applied to a variety of measurement sites on a patient's skin including any location on the forehead and temples or other location of the head. One example of a sensor 120 configured for placement on a patient's forehead is described below with respect to FIG. 3. The sensor 120 generally includes one or more electrodes and is configured to measure the electrical activity within the patient's head and generate an EEG signal, as discussed in further detail below.

In some embodiments, the sensor's electrodes are designed to be placed at a measurement site covered with a patient's hair. A caregiver or patient may fasten the sensor 120 to the patient's head with a variety of mechanism including adhesive, straps, caps, combinations of the same, or other devices for fastening sensors to a patient's body or skin known in the art.

In some embodiments, the communication link 150 and/or the control link 170 are wired electrical connections (e.g., an electrical cable, etc.). In other embodiments, the communication link 150 and/or the control link 170 utilize wireless communication to provide portability, and greater flexibility in depth of consciousness monitor placement with respect to the drug delivery device 160. Wireless communications also help accommodate an ambulatory patient, or other patient in transit. For example, in one embodiment, the depth of consciousness monitor 140 may be attached to an arm band or included in an arm band or other device that is wearable by the patient, including in a cap, a hood, a sling or a pocket of a garment. In such an embodiment, the sensor 120 communicates with the arm band depth of consciousness monitor 140 via a wired or a wireless connection.

In an embodiment, the depth of consciousness monitor 140 communicates wirelessly with the drug delivery device 160 over a wireless control link 170. This allows the depth of consciousness monitor 140 to be transported between various caregiving facilities, each with their own stationary drug delivery devices 160 without unhooking and reinserting hardwired electrical connections. Instead, the depth of consciousness monitor 140 could establish a wireless communication link with a stationary drug delivery device 160 as the depth of consciousness monitor 140 is brought into proximity with the drug delivery device 160. In an embodiment, the devices could establish the connection automatically and patient data may be automatically sent from the depth of consciousness monitor 140 to the drug delivery device 160. In other embodiments, caregiver interaction is required to establish a wireless control link 170 between the depth of consciousness monitor 140 and the drug delivery device 160. Such configurations advantageously facilitate portability and seamless monitoring of a patient while the patient is transported, for example, from an ambulance to a hospital room or from room to room within a hospital.

In an embodiment, the depth of consciousness monitor 140 also communicates with, or incorporates, a pulse oximeter (not shown). The pulse oximeter may be a multi-parameter monitor or other host device capable of monitoring a wide variety of vital signs and blood constituents and other parameters or combinations of parameters such as those monitors commercially available from Masimo Corporation of Irvine, Calif., and disclosed herein with reference to U.S. Pat. Nos. 6,584,336, 6,661,161, 6,850,788, and 7,415,297, among others assigned to Masimo Corporation, and U.S. Patent Publication Nos. 2006/0211924, 2010/0030040, among others assigned to Masimo Corporation or Masimo Laboratories, Inc. of Irvine Calif., all of which are incorporated by reference in their entireties.

The communication link 150 and the control link 170 can include any of a variety of wired or wireless configurations. For example, in some embodiments the links 150, 170 are implemented according to one or more of an IEEE 801.11x standard (e.g., a/b/g/n, etc.), a BLUETOOTH wireless standard, and a wireless medical information communications standard, etc.

The drug delivery device 160 generally includes at least a drug therapy interface 192, a drug flow device 194, and a flow controller 196. The drug therapy interface 192 receives a drug and provides a flow path to the drug flow device 194. For example, the drug therapy interface 192 can include a port or receptacle to receive or interface with a drug capsule, intravenous bag, syringe, etc. The drug flow device 194 receives the drug therapy from the drug therapy interface 192 and allows the drug to flow to the patient 180 via the conduit 190. In some embodiments, the drug flow device 194 includes one or more of a solenoid, a pump, a valve, a peristaltic pump, a variable speed pump, a compression sleeve (e.g., to squeeze an intravenous bag), etc. The action and activation of the drug flow device 194 is controlled by the flow controller 196. The flow controller 196 includes a microcontroller, a memory, a signal input to receive a control signal from the depth of consciousness monitor 140 via the control link 170 and a signal output to provide control over the functionality of the drug flow device 194. The signal input can include a wireless radio to facilitate wireless communication over a wireless control link 170. The signal input allows closed-loop control over the operation of the drug delivery device 160, as will be described in greater detail below.

In some embodiments, the drug delivery device 160 is manually controlled by a clinician (e.g., an anesthesiologist) and/or includes a manual override to allow the clinician to take control over drug delivery to the patient 180. Therefore, in some embodiments, the depth of consciousness monitoring system 100 does not include an electronic control link 170 between the depth of consciousness monitor 140 and the drug delivery device. Instead, in such an open-loop configuration, the depth of consciousness monitor 140 displays an indication of the patient's depth of consciousness. The clinician is able to manually adjust drug therapy to the patient in response to the signals displayed by the depth of consciousness monitor 140.

In some embodiments, the depth of consciousness monitor 140 is configured to generate and/or provide a delay signal (which is form of delay information) to the drug delivery device 160. The delay signal may be used by the drug delivery device to control whether the depth of consciousness monitoring system 100 is operating under positive or negative feedback. In some embodiments, the drug delivery device 160 controls or delays the delivery of drugs provided to the patient 180 in response to the delay signal. For example, the drug delivery device 160 may delay drug deliver to make sure that the depth of consciousness monitoring system 100 is operating under negative feedback, and is therefore a stable control system.

The delay signal can be determined by the depth of consciousness monitor 140 in any of a variety of manners. In one embodiment, the depth of consciousness monitor 140 time stamps the data received from the sensor 120 and provides the time stamp information or other related time information to the drug delivery device 160 as the delay signal. For example, in some embodiments, the delay signal includes the time stamp associated with the data received from the sensor 120 as well as a time stamp associated with the time the control signal data packet is sent to the drug delivery device 160. In other embodiments, the delay signal includes the difference between the two time stamps. In some embodiments, the drug delivery device 160 is configured to calculate or otherwise determine the appropriate control delay based upon the delay signal. For example, the drug delivery device 160 may time stamp the time the control signal is received from the depth of consciousness monitor 140. The drug delivery device 160 can determine a control delay based upon the difference between the time the control signal is received from the depth of consciousness monitor 140 and the time the depth of consciousness monitor received the signal from the sensor 120 that was used to generate the associated data packet received by the drug delivery device. The signal propagation delay through the depth of consciousness monitoring system 100 may be used to keep the system's feedback negative to avoid oscillation and to achieve stability.

In an embodiment, a caregiver or the patient may attach the depth of consciousness monitor 140 directly to the patient's arm or other part or clothing of the patient through an armband with straps or some other means known in the art to connect a portable monitoring unit to a patient. In an embodiment, a depth of consciousness monitor 140 may be integrated into a hat or other headgear wearable by the patient or some other structure near the patient. In an embodiment, the depth of consciousness monitor 140 can rest on a table or other surface near the patient.

In some embodiments, a depth of consciousness monitor 140 is integrated with the drug delivery device 160. Alternatively, the depth of consciousness monitor 140 could be a module that is docked or otherwise attached to the drug delivery device 160. The depth of consciousness monitor 140 can communicate with and/or be integrated with a variety of other device, such as a pulse oximeter, a respiration monitor, and EKG device, a blood pressure measurement device, a respirator, and/or a multi-parameter monitor.

FIG. 2 illustrates a block diagram of one embodiment of the depth of consciousness monitor 140, sensors 120, and drug delivery device 160. In an embodiment, the depth of consciousness monitor 140 includes a processor 220 which may be a micro-controller or other processor, to control and/or process signals received from the sensors 120. For example, the processor 220 may coordinate, process or condition, or manipulate the signals received from the sensor 120 to generate electronic data, control signals, and/or delay signals that are subsequently displayed and/or communicated to the drug delivery device 160. In addition, the processor 220 may receive instructions or data control messages from the drug delivery device 160 or other patient monitoring device to provide the appropriate conditioning and controlling of the various front end components of the sensors 120. Data transmitted between the depth of consciousness monitor 140, the drug delivery device 160, the sensors 120 and any other associated components, devices, or systems in communication with the depth of consciousness monitoring system 100 may be communicated by the devices using one or more interfaces, e.g., electrical wires, wireless communication, optical communication, RFID, LAN networks, or other electronic devices for communicating data known in the art.

The depth of consciousness monitor 140 may also include various front end components to enable the depth of consciousness monitor 140 to process the various signals received by the various sensors 120 that may be communicating with the depth of consciousness monitor 140. In an embodiment, front end components may translate and transmit instructions and control signals for driving the various sensors. In an embodiment, the front end components may translate, process, or transmit instructions and control signals to the emitting or light producing components of the sensor. The front end components may also receive and transmit data acquired by the detectors of the sensors to the microcontroller 220 or other processor 220. The front end components can include one or more of an analog-to-digital converter, a preamplifier, an amplifier, a filter, a decimation filter, a demodulator, etc.

These front end components could include front end components for a variety of sensors 120 including for sensors that detect blood oxygenation, EEG, EMG, ECG, temperature, acoustic respiration monitoring (“ARM”) sensors, such as those available from Masimo Corporation of Irvine, Calif., acoustic throat respiratory sensor, and brain oxygenation. In an embodiment, a caregiver could advantageously utilize a device with the ability to monitor the plurality of above mentioned parameters to more accurately determine a depth of a patient's sedation. However, in some embodiments, the depth of consciousness monitor 140 only includes EEG and EMG front end components. In an embodiment, a front end component that would be associated with a sensor 120 that detects brain oxygenation may have a sub component dedicated to driving emitters 230 associated with a light source of the brain oxygenation sensor and a sub-component associated with the detector 230 or detectors 230 of the brain oxygenation sensor 300 for receiving and transmitting the detected signals that pass through various body tissues. In other embodiments, the light drivers and detector front end are omitted.

In an embodiment, one of the various sensors associated with the front end components of the brain oximetry unit could be, for example, a blood oxygenation sensor 310 which may be placed at various measurement sites on a patient's skin, including the earlobe, finger, forehead or other places known in the art suitable for detecting blood oxygenation. Many suitable pulse oximeter sensors 310 are known in the art such as those blood oxygenation sensors 310 commercially available from Masimo Corporation of Irvine, Calif., including but not limited to those described in U.S. Pat. Nos. 5,638,818, 6,285,896, 6,377,829, 6,580,086, 6,985,764, and 7,341,559, which are expressly incorporated by reference in their entireties.

In an embodiment, a temperature sensor 320 communicates with an associated front end component of the depth of consciousness monitor 140. The temperature sensor 320 detects the temperature of the skin, the temperature inside the ear, the temperature under the tongue, or any other temperature measurement method known in the art. In an embodiment, the temperature sensor 320 could be any suitable thermistor, or any other temperature sensor 320 known in the art capable of detecting a surface temperature of a patient's skin. Additional temperature sensor may advantageously provide feedback to the depth of consciousness monitor 140 regarding the performance or temperature of one, combinations of, or all of the emitters 230.

An EEG sensor 330 may also be associated with the front end components of the depth of consciousness monitor 140. In an embodiment, the EEG sensor 330 may be any of a variety of EEG sensors 330 known in the art. An EEG sensor 330 could be applied to a patient at any of a multitude of locations and measurement sites on the skin of the head of a patient. In an embodiment, the EEG sensor 330 may include electrode leads that may be placed on a measurement site in contact with the skin of the patient. In an embodiment, the EEG 330 may monitor the electrical activity of a patient's brain through any number of electrodes, electrode leads, and channels or other systems known in the art. One such EEG sensor 330 is illustrated in FIG. 3 and described in greater detail below.

In an embodiment, the EEG sensor 330 may monitor and collect data from a patient's brain using 4 channels and 6 electrodes. In another embodiment, the EEG 330 may use 3 channels and 5 electrodes. In another embodiment, any variety or combination of sensors maybe be used that are suitable for obtaining an EEG signal, such as those described in U.S. Pat. Nos. 6,016,4444, 6,654,626, 6,128,521, which are incorporated by reference in their entireties.

A brain oxygenation sensor 300 may also be associated with the front end components of the depth of consciousness monitor 140. In an embodiment, the brain oxygenation sensor 300 includes a light source 230, and a detector 260. The light source 230 of the brain oxygenation sensor 300 includes emitter(s) that would emit light, sonic or other radiation into the forehead at one, two or other plurality of measurement sites located on the skin of the patient at a plurality of predetermined wavelengths. In an embodiment, the brain oxygenation sensor 300 would include a detector 260 with photodiodes or other radiation detection devices to detect the radiation emitting from the patient at a one or two or a plurality of measurement sites on the skin of the head of a patient. Many suitable brain oxygenation sensors 300 and cerebral oximeters are known in the art including those disclosed in U.S. Pat. Nos. 7,072,701, 7,047,054, which are expressly incorporated by reference in their entireties.

In an embodiment, the light source 230 of the brain oxygenation sensor 300 may include an emission detector 260. In an embodiment, the emission detector 260 detects the light emitted from the light source 230 before passing through or contacting the measurement site of the patient. In an embodiment, an output from the emission detector 230 would be communicated to the micro-controller 220 of the depth of consciousness monitor 140 in order to calculate an approximate output intensity of the light emitted by the emitter(s) 230. The micro-controller 220 or other processor 220 could calculate the output intensity based on the output of the emission detector 260 by comparing the data to calibration data. In an embodiment, the calibration data could include measurement of intensity of light emitted from the emitter(s) 230 and corresponding measurements of output from the emission detector 260. This data could then be correlated to real time output from the emission detector 260 while the oxygenation sensor 230 is in use to determine an actual or approximate intensity of light or radiation being emitted by the emitter(s) 230 utilizing a calibration curve or other suitable calculation or processing method. In an embodiment, the calibration data may be stored in an EPROM or other memory module in the depth of consciousness monitor 140 or other patient processing module or device associated with the patient monitoring system 100.

In an embodiment, the detector 260 detects light or other radiation emitted from the light source 230 after, in an embodiment, some of the light has entered the measurement site on the patient and has been attenuated by a patient's tissue. In an embodiment, the detector 260 could be any number of detectors known in the art for detecting light or other radiation including photodiodes or other types of light or radiation detectors. In one embodiment, the detector 260 may convert detected light or other radiation into a signal, for example, an electrical output signal, which may represent the intensity or other attributes of the radiation. In an embodiment, the signal from the detector 260 may be sent to a brain oxygenation detector 260 front end located in the depth of consciousness monitor 140 for processing, conditioning or transmitting to a pulse oximeter (not shown) or other patient monitoring processor. In one embodiment, the signal may be converted into a digital format by an analog to digital converted located in the depth of consciousness monitor 140. In an embodiment, the data from the detector 260 of the brain oxygenation sensor 300 may be processed to determine the cerebral oxygenation of a patient's brain tissue. In an embodiment, the processing of the data may include determining the changes of intensity between various wavelengths of emitted and detected light of the cerebral oxygenation sensor 300.

In an embodiment, a cerebral oximeter or multi-parameter monitor (not shown) acquires data from the depth of consciousness monitor 140 or sensor 120 derived from physiologically relevant parameters. In an embodiment, the pulse oximeter could provide visual quantitative or qualitative assessments of the patient's well-being based on one or more of the various parameters or physiological attributes measured.

In an embodiment, a caregiver may utilize various physiological parameters to make a quantitative assessment of the patient's depth of sedation as indicated by an index based on for example, a patient's temperature, electroencephalogram or EEG, brain oxygen saturation, stimulus response, electromyography or EMG, respiration based on acoustic through sensors, body oxygen saturation or other blood analytes, pulse, hydration, blood pressure, perfusion, or other parameters or combinations of parameters. In another embodiment, various aspects of sedation could be assessed quantitatively or qualitatively based on a visual representation of the patient's sedation in the aspects including hypnosis, responsiveness, muscle relaxation or other clinically relevant facets of depth of anesthesia.

In an embodiment, the functionality of the depth of consciousness monitor 140 could be optionally controlled by the drug delivery device 160. In an embodiment, the data and qualitative and quantitative assessments of a patient's wellness being could be displayed on one or more of the depth of consciousness monitor 140, the drug delivery device 160, or any other device or system in communication with the depth of consciousness monitoring system 100 (e.g., a pulse oximeter, physiological patient monitor, nurse station, etc.). Also, audible alarms and other indicators could be displayed on either or both the depth of consciousness monitor 140 and drug delivery device in response to various threshold breaches based on the assessment of the patient's wellness and depth of consciousness as determined from the various monitored parameters.

FIG. 3 illustrates one embodiments of a sensor 120 in the form of an EEG sensor 410, which is configured for placement on a patient's forehead to generate an EEG signal. Disposable and reusable portions of the sensor 410 may be connected and overlayed on top of one another. The EEG sensor 410 includes six EEG electrodes 440 with two reference electrodes (along the central axis of the EEG sensor 410) and four active channel electrodes (two on each side of the EEG sensor's central axis). In some embodiments, light source(s) and light detector(s) (not shown) may be incorporated into the EEG sensor 410, as well. All or some of the above mentioned sensor components including the EEG electrodes 440, leads from the electrodes 440, and blood oxygen detecting light emitters and detectors (when provided) may communicate with one or more chips 420 that enables transmission of acquired signals and drive signals. In some embodiments a single chip 420 is provided. In other embodiments, each component communicates with its own individual chip through wires, or printed circuits, or other suitable electrical connections.

The EEG electrodes 440 may be any suitable electrodes for detecting the electro-potentials on the surface of the skin of a patient's head. In one embodiment, EEG electrodes 440 include a metal or other suitable conductor and utilize leads contacting the surface of the skin. In another embodiment, the electrodes 440 are gelled electrodes that make contact through the skin via gel and have metal leads that come into contact with the gel. In still yet another embodiment, the EEG electrodes 440 may be glued to the forehead with any suitable patient dermal adhesive for connecting the EEG electrodes 440 and may have electrical conductivity. In an embodiment, potentials from the EEG electrodes 440 are transmitted to the depth of consciousness monitor 140 for further conditioning, transmitting or processing.

The sensor 410 may also include one or more temperature sensors (not shown). The temperature sensor may be any suitable sensor that can detect the temperature of the surface of the skin or other patient temperatures. In an embodiment, the temperature sensor may include a thermistor attached to a reusable portion of the sensor 410.

In an embodiment, the sensor 410 includes an interface 450 to couple the sensor 410 to the depth of consciousness monitor 140. The interface 450 may be any suitable electrical or data connection or communication port or device including, for example, a pin connector and receiver. Various other communication or electrical connections known in the art may be utilized. In an embodiment, the interface 450 may include an inductance connection utilizing transformers to couple a data and electrical connection across an insulator. In another embodiment, the interface 450 provides a data or electronic coupling between a reusable portion and a disposable portion of the sensor 410.

In some embodiments, the sensor 410 includes a disposable portion (not shown) removably attached to a reusable portion (not shown). In an embodiment, the disposable portion attaches to a measurement site of a patient's head and provides a base to which the reusable portion may be docked, mated or connected. The disposable portion houses the components of the sensor 410 that may be less expensive than at least some of the components contained in the reusable portion, and therefore may be disposed after a single or multiple uses, either on the same patient or different patients. The disposable portion of the sensor 410 includes a tape substrate that provides a base or substrate to which at least some of the components of the disposable portion may adhere or be integrated. In an embodiment, the tape can be constructed from any suitable disposable material that will effectively hold the components includes in the disposable portion to a patient's forehead or other measurement site. In an embodiment, the tape includes a suitable dermal adhesive on a patient side of the disposable portion for temporary adhesion of the sensor to a patient's skin.

In an embodiment, the sensor 410 may include an adhesive tape 430 that supports the EEG electrodes 440. In one embodiment, the EEG electrodes 440 may be fastened to the tape 430. In an embodiment, the EEG electrodes 440 could be embedded in the tape 430 by any known adhesive in the sensor arts or any other suitable means for connecting the EEG electrodes 440 that would allow the EEG electrode 440 leads to be exposed on a patient side of tape 430 in an appropriate position to come in close proximity to a measurement site of a patient's skin. In an embodiment, EEG electrodes 440 may be gelled so that the gel contacts the electrodes and a measurement site of a patient's skin to provide an electrical path between the measurement site of the patient's skin and the EEG electrodes 440. In an embodiment, the leads of the EEG electrodes 440 are connected to a chip 420 by wires or other suitable electrical connections, such a as a printed circuit, flex circuit, etc.

The sensor 410 may also include a temperature sensor (not shown). In an embodiment, the temperature sensor includes a thermistor with the thermistor leads exposed on a patient contacting side of the tape 430, in order to facilitate the contacting of the leads of temperature sensor to a measurement site of a patient's skin. In an embodiment, the temperature sensor is connected to single chip through wires or other suitable electrical connections such as a flexible printed circuit. In an embodiment, the temperature sensor may be located anywhere on the tape 430, the disposable portion or the reusable portion of the sensor 410 (if the sensor is provided with disposable and reusable portions). In an embodiment, the leads for the temperature sensor may be near the center of tape 430 or anywhere on the periphery of tape 430.

In some embodiments, the sensor 410 includes a pulse oximeter sensor (not shown). The pulse oximeter sensor can include an ear pulse oximeter sensor that emits and detects radiation to determine the oxygenation of the blood travelling through the arteries of the ear. Many suitable ear pulse oximeter sensors are known in the art such as those sensors commercially available from Masimo Corporation and disclosed herein with reference to U.S. Pat. No. 7,341,599, which is expressly incorporated by reference in its entirety. In another embodiment, the pulse oximeter sensor may be a forehead pulse oximeter sensor or any other suitable pulse oximeter known in the art or disclosed herein. The pulse oximeter sensor may be connected to the sensor 410 through electrical wires, wirelessly or other suitable electrical or data connection. Data collected from the pulse oximeter sensor may be transmitted to the depth of consciousness monitor 140, pulse oximeter, or both for conditioning and further processing.

In some embodiments, signal processing and conditioning circuitry of depth of consciousness monitor configured to monitor the EEG signals of a patient and providing feedback on the depth of sedation or awareness of a patient undergoing anesthesia, may be partially or entirely incorporated into the sensor 410. Sedation brain function monitors, including those similar to the SEDLINE sedation monitor commercially available from Masimo Corporation of Irvine, Calif., as well as those described in U.S. Pat. Nos. 6,128,521, 6,301,493, 6,317,627, 6,430,437, all of which are expressly incorporated by reference in their entireties. For example, the sensor's connector or interface 450 may house the circuit board, with six channels for six detectors and a processor configured to determine depth of consciousness.

Integration of all or the majority of the associated circuitry and processing components of several different patient monitoring sensors in a single sensor advantageously provides a caregiver a simple device that can be attached to the patient's forehead and/or other areas on the patient, to provide minimal discomfort to the patient and minimal amount of wires and connections to cause electrical interference with instruments in the hospital environment. Additionally, the caregiver will spend less time attaching various sensors to a patient where each would otherwise require its own associated monitoring station. Furthermore, integration of sensor processing components allows some of the processing components to have shared functionality and therefore saves considerably on manufacturing costs. For example, memory chips, processors, or other electrical components may be shared by the various sensors.

EEG Signal Processing

Referring again to FIG. 2, the depth of consciousness monitor's processor 220 is configured to receive at least an EEG signal from an EEG sensor 330 using an interface, such as an EEG interface 332 and process the EEG signal to determine the patient's depth of consciousness. In some embodiments, the processor 220 determines an index value between 0 and 100 to indicate depth of consciousness. The depth of consciousness monitor 140 may include a display, such as a monitor, LED, speaker, etc., to indicate the patient's depth of consciousness, e.g., the index value.

In some embodiments, the processor 220 determines the frequency content of the EEG signal prior to administration of any sedatives as well as during sedation. FIG. 4 illustrates one embodiment of a graph 500 showing the patient's EEG's frequency content or frequency spectrum prior to sedation as curve 510 and during sedation as curve 530. Shifting of the curve 510 amplitude at frequencies below 10 Hz, a drop in curve slope at frequencies above 10 Hz, and the formation or increase in the frequency curve 510 to form a local maximum (e.g., local maximum 540) at 10 Hz each indicates that the patient has entered a sedated state.

Indeed, in one embodiment, the processor 220 determines whether the patient is adequately sedated by monitoring for the presence of a local maximum 540 in the frequency curve 530 above a predetermined threshold value, at 10 Hz. However, the shape of the frequency curve 530 can vary based upon several factors, such as any one or more of the patient's age, age classification (e.g., pediatric, adult, geriatric, etc.), sex, weight, body-mass index, genetic factors, etc. The shape of the frequency curve 530 can also vary based upon one or more physiological parameters associated with the patient, such as the patient's temperature, blood oxygen concentration, EMG signal, etc. Furthermore, the shape of the frequency curve 530 can also vary based upon the particular drug administered to sedate the patient. For example, the drug type, drug class (e.g., hypnotic, analgesic, opiate, etc.), mechanism or method of delivery (inhalant, intravenous, ingestible, etc.) and/or particular active ingredient (e.g., Propofol (TIVA), Sevoflurane, nitrous oxide, morphine, etc.) can each affect the shape of the frequency curve 530. Variations in the frequency curve 530 make it more difficult for the depth of consciousness monitor 140 to accurately determine whether the patient is adequately sedated.

Therefore, to improve accuracy, in one embodiment the depth of consciousness monitor's processor 220 analyzes the frequency curve 530 by considering one or more curve profiles associated with the patient and/or the drug administered. For example, in one embodiment, the processor 220 obtains physiological information regarding the patient from sensors 120 attached to the depth of consciousness monitor 140. In other embodiments, the processor 220 obtains physiological information regarding the patient via a data port. For example, the data port can receive temperature, blood oxygen saturation, respiration rate, and/or other physiological parameter information from an separate monitor. In addition, the depth of consciousness monitor 140 can receive additional information regarding the patient and the drug via the data port, as well.

For example, in some embodiments, the data port includes a wireless radio, a network adapter, a cable, an Ethernet adapter, a modem, a cellular telephone, etc., to receive patient and/or drug information. The patient and/or drug information is provided to the processor 220 to accurately interpret the frequency curve 530 derived from the EEG sensor 330 signal. In one embodiment, the data port includes a keyboard or other data entry device that allows the clinician to manually inter data relating a patient or drug parameters, such as those examples described above. Indeed, the processor 220 can include one or more EEG processing engines that are configured based upon the patient and/or drug data received by the depth of consciousness monitor 140, as discussed in greater detail below.

In some embodiments, the patient's frequency response graph 500 is processed as four distinct, non-overlapping frequency bands 550, 552, 554, 556.

For example, the first frequency band, sometimes referred to as the delta band, is the portion of the graph 500 between 0 and 4 or about 4 Hz. The second frequency band, sometimes referred to as the theta band, is the portion of the graph 500 between 4 or about 4 Hz and 7 or about 7 Hz. The third frequency band, sometimes referred to as the alpha band, is the portion of the graph 500 between 7 or about 7 Hz and 12 or about 12 Hz; and the fourth frequency band, sometimes referred to as the beta band, is the portion of the graph 500 greater than 12 or about 12 Hz.

In some embodiments, the depth of consciousness monitor 140 determines whether there is a peak 540 greater than a predetermined threshold in the frequency curve 530 anywhere within the alpha band 554. If so, the monitor 140 may determine that the patient is adequately sedated. However, in some cases, the peak 540 can shift and appear outside of the alpha band 554. For example, a sedated patient that is experiencing hypothermia may not manifest a peak in the alpha band; instead, the peak may shift to the theta or beta bands.

Therefore, in one embodiment, the depth of consciousness monitor 140 does not limit its search for a peak 540 to a particular frequency value (e.g., 10 Hz) or a particular frequency band (e.g., alpha band 554). Instead, in such an embodiment, the depth of consciousness monitor 140 scans across all frequencies (or a larger subset of frequencies than just those within the alpha band) to search for a peak 540 (e.g., across two or more frequency bands). A detected peak may be used to determine alone (or in combination with other patient and/or drug data) whether the patient is adequately sedated.

The peak 540 can be defined in any of a variety of clinically-relevant manners. For example, the peak 540 can be defined based upon the slope of the curve segment on one or both sides of the peak 540, the relative magnitude of the peak compared to the curve values at predetermined locations or offsets on either side of the peak 540, the relative magnitude of the peak compared to the frequency curve 510 of the patient obtained prior to sedation, etc.

In one embodiment, the processor 220 processes the patient's frequency spectra curve 510, 530 as deformable curves by utilizing motion vector processing. For example, the processor 220 compares each point (or a predetermined number of points) in the pre-sedation curve 510 to points within the sedation frequency curve 530 to match points having the greatest similarity (e.g., relative position with respect to its neighbors, pattern matching, sum of absolute differences, any pattern matching technique, etc.). The processor 220 determines one or more motion vectors 560 to describe the motion of the points from one curve 510 to the next 530. Each motion vector 560 includes both direction and amplitude (e.g., distance traveled) information. Although the graph 500 includes curve 510, 530 illustrated in the frequency domain (the x-axis represents frequency), the motion vectors 560 include time domain information. For example, the processor 220 can look at multiple frames of data (e.g., multiple graphs 500) and employ pattern matching techniques (e.g., sum of absolute differences) to determine which points in the graphs 500 and their curves 510, 530 to use to define the respective motion vectors 560. In some embodiments, the motion vectors 560 are determined at 0.5, 1, 2, or 2.5 Hz intervals.

One or more motion vector 560 profiles may be constructed based upon particular drug and patient data. For example, each drug used for sedation may be characterized by a unique set of motion vectors. When a patient is treated with a particular drug, and the patient's motion vectors match those of the drug (e.g., the drug profile), the processor 220 can determine that the patient is adequately sedated. Such profiles may be determined for any one or more of the patient's age, age classification (e.g., pediatric, adult, geriatric, etc.), sex, weight, body-mass index, genetic factors, etc., physiological parameters associated with the patient, such as the patient's temperature, blood oxygen concentration, EMG signal, etc., the particular drug administered to sedate the patient, the drug type, drug class (e.g., hypnotic, analgesic, opiate, etc.), mechanism or method of delivery (inhalant, intravenous, ingestible, etc.) and/or particular active ingredient (e.g., Propofol (TIVA), Sevoflurane, nitrous oxide, morphine, etc.). Such profiles may be stored within the depth of consciousness monitor's memory, or they may be retrieved from one or more data repositories stored at one or more remote locations (e.g., over a computer network, over the Internet, from a server, from the cloud, etc.).

In another embodiment, the EEG front end circuitry is configured not to eliminate or filter out low frequencies. The EEG front end circuitry instead allows the processor 220 to determine slow waves (e.g., time-domain signals at or below 1, 0.5, and/or 0.2 Hz). The processor 220 can employ one or more phase coherence methods to detect phase coherence between one or more slow waves and one or more patient signals falling within one of the frequency bands 550, 552, 554, 556. For example, in some embodiments, phase coherence between a slow wave and a signal from the theta band 552 indicates that the patient is awake. One the slow wave and signal from the theta band 552 are out of phase, the patient is sedated. In other embodiments, phase coherence analysis is performed to compare phase coherence between a selected slow wave and a different frequency band's signals (e.g., the delta band 550, the alpha band 554, and/or the beta band 556). In some embodiments, the processor 220 performs phase coherence analysis between a selected slow wave and multiple signals between 4 and 50 Hz, e.g., every 0.2, 0.5, 1, or 2 Hz. In other embodiments, phase coherence is determined along the entire frequency spectrum.

In yet another embodiment, the processor 220 generates and/or utilizes a mathematical or electrical model of brain activity to determine whether the patient is adequately sedated. The model can be used to predict what the EEG of a sedated patient should look like based upon a particular drug, drug delivery mechanism, concentration (or any other drug parameter, including those discussed above). Actual EEG signals may be compared to the signal predicted by the model to determine whether the patient is adequately sedated. The model can be constructed of various combinations of electrical components (e.g., resistors, capacitors, amplifiers, etc.) or computing elements.

In one embodiment, brain modeling occurs by storing EEG signals from sedated patients in a memory location and categorized the EEG signals based upon any of a variety of drug and patient data information. For example, sedated EEG signals may be categorized based upon the particular drug, dosage, concentration, delivery method, etc. used to treat the patient. A brain response model is constructed by combing the various data into a single model.

In some embodiments, the processor 220 includes a pre-processor 602, a compute engine 604, and a post processor 606, as illustrated in FIG. 5. The patient's EEG signal is received by the pre-processor 602. The pre-processor 602 performs front end processing, such as one or more of filtering, amplification, ND sampling, decimation, demodulation, etc. of the EEG signal. In some embodiments, the pre-processor 602 includes the EEG front end functionality discussed above with respect to FIG. 2. The compute engine 602 determines the level of patient sedation and/or depth of consciousness utilizing, for example, any of the techniques described herein. In one embodiment, the compute engine 602 determines an index value representative of the patient's sedation level. The post-processor 606 provides an indication of the patient's sedation level as well as other relevant information (e.g., system delay, as discussed above, other physiological parameter information, pass-through signals, etc.) for display to the clinician and/or transmission to a drug delivery device or other physiological monitor or information display station. In some embodiments, the post-processor 606 stores patient sedation, EEG signals, patient data and drug information in a memory location.

Another embodiment of a processor 220 is illustrated in FIG. 6. The processor 220 includes a pre-processor 602, multiple compute engines 604a, 604b, . . . 604n, and decision logic 608. Each compute engine 604a, 604b, . . . 604n determines patient sedation information utilizing different processing approaches. For example, one compute engine 604 may determine patient sedation information utilizing motion vector analysis (e.g., as discussed above), one compute engine 604 may determine patient sedation information utilizing frequency coherence analysis (e.g., as discussed above), etc. Furthermore, each compute engine 604 can be drug or patient information specific. For example, the compute engine 604 may utilize historical information (either of the patient himself or from a model, etc.) to determine patient sedation. Each compute engine 604 could therefore correspond to a particular patient's age, age classification (e.g., pediatric, adult, geriatric, etc.), sex, weight, body-mass index, genetic factors, etc., physiological parameters, such as temperature, blood oxygen concentration, EMG signal, etc., the particular drug administered to sedate the patient, such as the drug type, drug class (e.g., hypnotic, analgesic, opiate, etc.), mechanism or method of delivery (inhalant, intravenous, ingestible, etc.) and/or particular active ingredient (e.g., Propofol (TIVA), Sevoflurane, nitrous oxide, morphine, etc.). The compute engines 604 may operate simultaneously to parallel process EEG information.

A decision logic module 608 receives the outputs of each compute engine 604 and applies logic to determine the best estimate of the patient's sedation level. For example, in some embodiments, the decision logic module 608 averages or weighted averages the outputs of the compute engines 604. In other embodiments, the decision logic module 608 selects one or more compute engine outputs based upon known information about the patient and/or drug(s) used for sedation. The decision logic output 610 can indicate one or more parameters relevant to patient sedation. For example, in some embodiments, the decision logic output 610 includes suppression bar, EMG estimation, patient sedation index, drug type and patient age estimates. If any one or more decision logic outputs do not match actual drug or patient profile information, an alarm can activate. In other embodiments, the clinician manually compares the decision logic outputs to actual drug and patient profile information to confirm the accuracy of the depth of consciousness monitor 140.

Another embodiment of a depth of consciousness monitor's processor 220 is illustrated in FIG. 7. The processor 602 includes a pre-processor 602, compute engines 604 and decision logic 608, as discussed above with respect to FIG. 6. In addition, the processor 220 includes an EEG engine 620 and an EMG engine 630. The EEG and EMG engines receive a pre-processed EEG signal from the pre-processor 602. The pre-processed EEG signal will generally contain both EEG and EMG content. For example, EEG content describes the electrical activity within the patient's brain and the EMG content describes the electrical activity associated with the muscular contractions in the patient's forehead, near the EEG sensor. The EEG and EMG engines 620, 630 separate the EEG and EMG content from the pre-processed EEG signal. The outputs of the EEG and EMG engines 620, 630 communicate with the inputs of one or more compute engines 604. The EEG signal from the EEG engine provides an indication of the patient's hypnotic state, while the EMG engine provides an indication of the patient's analgesic response, or pain state. Separating the two provides more information about the patient's state, and allows improved depth of consciousness processing. When EMG content is included in the EEG signal, the frequency response curve is flatter at higher frequencies (e.g., at frequencies in the beta band).

FIG. 8 illustrates one embodiment of a process 700 to determine a patient's sedation level that can be implemented by any of the processors described above. The process 700 begins at block 702. At block 702, the process 700 receives an EEG signal from a patient. At block 704, the process 700 receives treatment data. The treatment data may include one or more of patient data and drug profile information. The patient data can include any of the patient data or drug profile information described above. At block 706, the process 700 selects a computing engine based upon one or more treatment data. At block 708, the process 700 computes patient sedation information using EEG information and the selected computing engine. The patient sedation information can include one or more of a patient sedation level or index, an EMG level, a prediction of the drug used to sedate the patient, a prediction of the patient's age, etc. The process 700 ends at block 708.

FIG. 9 illustrates another embodiment of a process 800 to determine a patient's sedation level that can be implemented by any of the processors described above. The process 800 begins at block 802. At block 802, the process 800 receives an EEG signal from a patient. At block 804, the process 800 receives treatment data. The treatment data may include one or more of patient data and drug profile information. The patient data can include any of the patient data or drug profile information described above. At block 806, the process 800 computes patient sedation information with parallel computing engines using the EEG information. The patient sedation information can include one or more of a patient sedation level or index, an EMG level, a prediction of the drug used to sedate the patient, a prediction of the patient's age, etc. At block 808, the process 800 determines patient sedation information by selecting the output of one of the parallel computing engines, or by combining one or more computing engine outputs (e.g., averaging, weighted averaging, etc.). The process 800 ends at block 808.

FIG. 10 illustrates one embodiment of a depth of consciousness monitoring system 1000. The system 1000 includes a depth of consciousness monitor assembly 1002, a multi-parameter monitor 1012, and a sensor 1014. The monitor assembly 1002 includes a depth of consciousness processor 1003, which can include any of the processors described above. In some embodiments, the processor 1003 is configured to perform one or more of the methods described above.

The assembly 1002 may be provided in the form of a cable. For example, the assembly 1002 may include one or more cables 1004 (or cable portions) that terminate in connectors 1005, 1008 located at the cable ends 1006, 1010. In the illustrated embodiment of FIG. 10, the assembly 1002 includes two cables 1004. The first cable 1004 has two ends and is coupled to the processor 1003 at one end and terminates at a connector 1005 at the other end 1006. In one embodiment, the connector 1005 (which is one embodiment of an interface, such as a multi-parameter monitor interface) is configured facilitate communication between the processor 1003 and a medical device, such as a physiological monitor, display instrument, and/or a multi-parameter monitor 1012, etc. In some embodiments, the connector 1005 receives power from a multi-parameter monitor 1012 to power the depth of consciousness processor 1003. In some embodiments, the processor 1003 is configured to consume less than about 250 mW, 500 mW or 1 W at about 4.75 V, 5 V or 5.25 V.

Physiological signals generated by the depth of consciousness processor 1003 are communicated to the multi-parameter monitor 1012 via the connector 1005. The multi-parameter monitor 1012 is configured to display one or more of the signals generated by the depth of consciousness processor 1003. In one embodiment, the cable 1004 that terminates at the multi-parameter monitor 1012 connector 1005 is configured to provide and/or receive power, ground, data +and data −signals. For example, in one embodiment, the cable 1004 includes four conductors, one each for power, ground, data +and data −.

An adapter or coupler (not shown) may be provided to facilitate coupling of the connector 1005 to the multi-parameter monitor 1012. For example, an adapter having first and second ends can be configured to have different shapes and pin configurations to allow communication and physical coupling of the connector 1005 to the multi-parameter monitor 1012. In some embodiment, the adapter (not shown) also includes conditioning circuitry to facilitate communication and/or power transmission between the multi-parameter monitor 1012 and the processor 1003. For example, the adapter may provide voltage regulation, electrical isolation, signal multiplexing, etc.

The second cable 1004 has two ends and is coupled to the processor 1003 at one end and terminates at a connector 1008 at the other end 1010. In one embodiment, the connector 1008 is configured to facilitate communication with a physiological sensor 1014, such as an EEG sensor, and/or any other sensor described above via an interface 1015 (e.g., interface 450 of FIG. 3). In one embodiment, power from the multi-parameter monitor 1012 is directly or indirectly (e.g., after further filtering, conditioning, pulsing, etc. by the processor 1003) communicated to the sensor 1014. Signals (e.g., e.g., measured patient signals) from the sensor 1014 are communicated to the processor 1003 via the interface 1015, which can be coupled to the connector 1008.

FIG. 11 illustrates another embodiment of a depth of consciousness monitoring assembly 1002 coupled to a multi-parameter monitor (sometimes referred to as a multi-parameter instrument) 1012. The multi-parameter monitor 1012 is configured to receive and display a plurality of physiological parameters received from a patient monitoring device, such as, but not limited to, the depth of consciousness monitoring assembly 1002. The multi-parameter monitor 1012 includes a display 1020. The display 1020 is configured to display a plurality of physiological signals 1022 related to a medical patient. In some embodiments, the display 1020 can be configured to display only selected or groups of physiological signals 1022. In some embodiments, the monitor 1012 can be configured to display a particular view or mode on the display 1020. The view or mode can include one or more pre-selected groupings of physiological signals to display. Examples of different views that may be provided via the display 1020 are discussed below with respect to FIGS. 14-16. Other views, in addition to or instead of those illustrated in FIGS. 14-16 may be displayed on the multi-parameter monitor 1012 display 1020, as well.

In some embodiments, the multi-parameter monitor 1012 also includes a removable module 1024. The removable module 1024 can include a physiological monitor configured to determine one or more physiological parameters associated with the medical patient. For example, in some embodiments, the removable module 1024 includes a respiration rate monitor, a blood oxygen saturation monitor, a blood gas monitor, a carbon monoxide monitor, an ECG monitor, an EKG monitor, a blood pressure monitor, a temperature monitor, a heart rate monitor, etc., or a combination of any one or more of the foregoing.

In the illustrated embodiment of FIG. 11, the depth of consciousness monitor assembly 1002 only includes one cable 1004. A first end of the cable 1004 terminates at a connector (not shown) that is attached to the multi-parameter monitor 1012. The second end of the cable 1003 includes the depth of consciousness processor 1003 and connector 1008, which are integrated within a single housing assembly. The connector end of a sensor 1014 is shown attached to the depth of consciousness monitor assembly's 1002 cable's 1003 second end.

FIG. 12 illustrates another embodiment of a depth of consciousness monitor assembly 1002. The processor 1003 is positioned between the ends 1006, 1010 of the assembly 1002. The length of the cable 1004 attached to the connector 1008 configured to attach to a sensor (not shown) may be shorter than the length of the cable 1004 attached to the connector 1005 configured to attach to the multi-parameter monitor (not shown). The shorter sensor cable 1004 length can provide additional comfort and less pulling on the sensor when attached to the patient. FIG. 13 illustrates the depth of consciousness monitor assembly 1002 coupled to a sensor 1014. The sensor 1014 can include any of the EEG sensors described above.

FIGS. 14-16 illustrate views of various parameters 1022 that may be displayed on the multi-parameter monitor 1012 display 1020. The embodiment of FIG. 14 illustrates an EEG view of a multi-parameter monitor 1012. The multi-parameter monitor 1012 view includes a numeric value indicator (e.g., EEG data, insufficient EEG data, patent state index (PSI) value), or any other value described herein, etc.), a bar-graph indicator, menu indicators, date and time indicators, message indicators, physiological waveform indicators, and system status indicators. The physiological waveform indicators can display each of the waveforms received from each electrode (e.g., R2, R1, L1) of an sensor 1014, such as an EEG sensor.

FIG. 15 illustrates a trend view of a multi-parameter monitor 1012. The multi-parameter monitor 1012 view includes a primary indicator or display and a secondary indicator or display. The primary indicator displays the trend of one or more physiological parameters (e.g., PSI, etc.) over time. One or more secondary indicators can display additional physiological parameters of the medical patient, including but not limited to, EMG, and SR. In one embodiment, the secondary indicators display information in the same format (e.g., waveform, solid waveform, bargraph, etc.) as the primary (e.g., trend plot) indicator, but at a smaller size. In other embodiments, the secondary indicators display information in a different format than the primary (e.g., trend plot, etc.) indicator. FIG. 16 illustrates a density spectral array view of a multi-parameter monitor 1012. The multi-parameter monitor 1012 view includes a spectral density indicator

Each of the displayed physiological parameters can be determined by the depth of consciousness processor 1003. In addition, the multi-parameter monitor 1012 can be configured to display any one or more of the parameters discussed above, as well as other parameters, such as signals from the removable module 1024, when provided.

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

Depending on the embodiment, certain acts, events, or functions of any of the processes or algorithms described herein can be performed in a different sequence, can be added, merged, or left out altogether (e.g., not all described operations or events are necessary for the practice of the algorithm). Moreover, in certain embodiments, operations or events can be performed concurrently, e.g., through multi-threaded processing, interrupt processing, or multiple processors or processor cores or on other parallel architectures, rather than sequentially.

The various illustrative logical blocks, modules, routines, and algorithm steps described in connection with the embodiments disclosed herein can be implemented as electronic hardware, computer software, or combinations of both. To clearly illustrate this interchangeability of hardware and software, various illustrative components, blocks, modules, and steps have been described above generally in terms of their functionality. Whether such functionality is implemented as hardware or software depends upon the particular application and design constraints imposed on the overall system. The described functionality can be implemented in varying ways for each particular application, but such implementation decisions should not be interpreted as causing a departure from the scope of the disclosure.

The steps of a method, process, routine, or algorithm described in connection with the embodiments disclosed herein can be embodied directly in hardware, in a software module executed by a processor, or in a combination of the two. A software module can reside in RAM memory, flash memory, ROM memory, EPROM memory, EEPROM memory, registers, hard disk, a removable disk, a CD-ROM, or any other form of a non-transitory computer-readable storage medium. An example storage medium can be coupled to the processor such that the processor can read information from, and write information to, the storage medium. In the alternative, the storage medium can be integral to the processor. The processor and the storage medium can reside in an ASIC. The ASIC can reside in a user terminal. In the alternative, the processor and the storage medium can reside as discrete components in a user terminal.

Conditional language used herein, such as, among others, “can,” “could,” “might,” “may,” “e.g.,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and/or steps. Thus, such conditional language is not generally intended to imply that features, elements and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without author input or prompting, whether these features, elements and/or steps are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.

Conjunctive language such as the phrase “at least one of X, Y and Z,” unless specifically stated otherwise, is to be understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z, or a combination thereof. Thus, such conjunctive language is not generally intended to imply that certain embodiments require at least one of X, at least one of Y and at least one of Z to each be present.

While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it can be understood that various omissions, substitutions, and changes in the form and details of the devices or algorithms illustrated can be made without departing from the spirit of the disclosure. As can be recognized, certain embodiments of the inventions described herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others. The scope of certain inventions disclosed herein is indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims

1. A depth of consciousness monitor configured to determine a level of sedation of a medical patient, the depth of consciousness monitor comprising: an EEG interface located within the depth of consciousness monitor and configured to receive an EEG signal from an EEG sensor;an EEG front end configured to pre-process the EEG signal;a processor, configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal, wherein the processor is further configured to determine delay information using a time the EEG signal is received by the EEG interface and a time the level of sedation is determined by the processor; anda drug delivery device interface, configured to provide the level of sedation and the delay information to a drug delivery device.
2. The depth of consciousness monitor of claim 1, further comprising a multi-parameter monitor interface configured to receive power from a multi-parameter monitor and provide to the multi-parameter monitor one or more of: (a) one or more physiological signals determined by the processor, (b) the level of sedation, or (c) the delay information.
3. The depth of consciousness monitor of claim 1, wherein the EEG front end comprises an EEG engine and an EMG engine configured to extract EEG information and EMG information from the EEG signal, respectively.
4. The depth of consciousness monitor of claim 1, wherein processor is further configured to time stamp the EEG signal when received from the EEG sensor.
5. The depth of consciousness monitor of claim 1, further comprising an additional sensor front end.
6. The depth of consciousness monitor of claim 5, wherein the additional sensor front end comprises an SpO2 sensor front end.
7. The depth of consciousness monitor of claim 1, further comprising a data port configured to receive at least one of patient data and drug profile information.
8. The depth of consciousness monitor of claim 7, wherein the processor is configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal and the at least one of patient data and drug profile information.
9. A depth of consciousness monitoring system comprising the depth of consciousness monitor of claim 1 and the EEG sensor.
10. A depth of consciousness monitoring system comprising the depth of consciousness monitor of claim 1 and the drug delivery system.
11. The depth of consciousness monitor of claim 1, wherein the drug delivery device interface comprises a wireless communication device.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority from U.S. Provisional No. 61/703,747, filed Sep. 20, 2012, and U.S. Provisional No. 61/656,974, filed Jun. 7, 2012, both of which are incorporated by reference in their entireties.

US Referenced Citations (969)

Number	Name	Date	Kind
3702431	Pinckaers	Nov 1972	A
3710041	Hayashi	Jan 1973	A
3719830	Ananiades	Mar 1973	A
4610259	Cohen	Sep 1986	A
4960128	Gordon et al.	Oct 1990	A
4964408	Hink et al.	Oct 1990	A
5041187	Hink et al.	Aug 1991	A
5069213	Polczynski	Dec 1991	A
5163438	Gordon et al.	Nov 1992	A
5319355	Russek	Jun 1994	A
5337744	Branigan	Aug 1994	A
5341805	Stavridi et al.	Aug 1994	A
D353195	Savage et al.	Dec 1994	S
D353196	Savage et al.	Dec 1994	S
5377676	Vari et al.	Jan 1995	A
D359546	Savage et al.	Jun 1995	S
5431170	Mathews	Jul 1995	A
D361840	Savage et al.	Aug 1995	S
D362063	Savage et al.	Sep 1995	S
5452717	Branigan et al.	Sep 1995	A
D363120	Savage et al.	Oct 1995	S
5456252	Vari et al.	Oct 1995	A
5479934	Imran	Jan 1996	A
5482036	Diab et al.	Jan 1996	A
5490505	Diab et al.	Feb 1996	A
5494043	O'Sullivan et al.	Feb 1996	A
5533511	Kaspari et al.	Jul 1996	A
5534851	Russek	Jul 1996	A
5561275	Savage et al.	Oct 1996	A
5562002	Lalin	Oct 1996	A
5590649	Caro et al.	Jan 1997	A
5602924	Durand et al.	Feb 1997	A
5632272	Diab et al.	May 1997	A
5638816	Kiani-Azarbayjany et al.	Jun 1997	A
5638818	Diab et al.	Jun 1997	A
5645440	Tobler et al.	Jul 1997	A
5685299	Diab et al.	Nov 1997	A
D393830	Tobler et al.	Apr 1998	S
5743262	Lepper, Jr. et al.	Apr 1998	A
5758644	Diab et al.	Jun 1998	A
5760910	Lepper, Jr. et al.	Jun 1998	A
5769785	Diab et al.	Jun 1998	A
5782757	Diab et al.	Jul 1998	A
5785659	Caro et al.	Jul 1998	A
5791347	Flaherty et al.	Aug 1998	A
5810734	Caro et al.	Sep 1998	A
5823950	Diab et al.	Oct 1998	A
5830131	Caro et al.	Nov 1998	A
5833618	Caro et al.	Nov 1998	A
5860919	Kiani-Azarbayjany et al.	Jan 1999	A
5890929	Mills et al.	Apr 1999	A
5904654	Wohltmann et al.	May 1999	A
5919134	Diab	Jul 1999	A
5934925	Tobler et al.	Aug 1999	A
5940182	Lepper, Jr. et al.	Aug 1999	A
5987343	Kinast	Nov 1999	A
5995855	Kiani et al.	Nov 1999	A
5997343	Mills et al.	Dec 1999	A
6002952	Diab et al.	Dec 1999	A
6011986	Diab et al.	Jan 2000	A
6016449	Fischell	Jan 2000	A
6027452	Flaherty et al.	Feb 2000	A
6036642	Diab et al.	Mar 2000	A
6045509	Caro et al.	Apr 2000	A
6067462	Diab et al.	May 2000	A
6081735	Diab et al.	Jun 2000	A
6088607	Diab et al.	Jul 2000	A
6110522	Lepper, Jr. et al.	Aug 2000	A
6124597	Shehada	Sep 2000	A
6128521	Marro et al.	Oct 2000	A
6129675	Jay	Oct 2000	A
6144868	Parker	Nov 2000	A
6151516	Kiani-Azarbayjany et al.	Nov 2000	A
6152754	Gerhardt et al.	Nov 2000	A
6157850	Diab et al.	Dec 2000	A
6165005	Mills et al.	Dec 2000	A
6184521	Coffin, IV et al.	Feb 2001	B1
6206830	Diab et al.	Mar 2001	B1
6229856	Diab et al.	May 2001	B1
6232609	Snyder et al.	May 2001	B1
6236872	Diab et al.	May 2001	B1
6241683	Macklem et al.	Jun 2001	B1
6253097	Aronow et al.	Jun 2001	B1
6256523	Diab et al.	Jul 2001	B1
6263222	Diab et al.	Jul 2001	B1
6278522	Lepper, Jr. et al.	Aug 2001	B1
6280213	Tobler et al.	Aug 2001	B1
6285896	Tobler et al.	Sep 2001	B1
6301493	Marro et al.	Oct 2001	B1
6308089	von der Ruhr et al.	Oct 2001	B1
6317627	Ennen et al.	Nov 2001	B1
6321100	Parker	Nov 2001	B1
6325761	Jay	Dec 2001	B1
6334065	Al-Ali et al.	Dec 2001	B1
6343224	Parker	Jan 2002	B1
6349228	Kiani et al.	Feb 2002	B1
6360114	Diab et al.	Mar 2002	B1
6366805	Lutz	Apr 2002	B1
6368283	Xu et al.	Apr 2002	B1
6371921	Caro et al.	Apr 2002	B1
6377829	Al-Ali	Apr 2002	B1
6388240	Schulz et al.	May 2002	B2
6397091	Diab et al.	May 2002	B2
6430437	Marro	Aug 2002	B1
6430525	Weber et al.	Aug 2002	B1
6463311	Diab	Oct 2002	B1
6470199	Kopotic et al.	Oct 2002	B1
6501975	Diab et al.	Dec 2002	B2
6505059	Kollias et al.	Jan 2003	B1
6515273	Al-Ali	Feb 2003	B2
6519487	Parker	Feb 2003	B1
6525386	Mills et al.	Feb 2003	B1
6526300	Kiani et al.	Feb 2003	B1
6541756	Schulz et al.	Apr 2003	B2
6542764	Al-Ali et al.	Apr 2003	B1
6580086	Schulz et al.	Jun 2003	B1
6584336	Ali et al.	Jun 2003	B1
6595316	Cybulski et al.	Jul 2003	B2
6597932	Tian et al.	Jul 2003	B2
6597933	Kiani et al.	Jul 2003	B2
6606511	Ali et al.	Aug 2003	B1
6632181	Flaherty et al.	Oct 2003	B2
6639668	Trepagnier	Oct 2003	B1
6640116	Diab	Oct 2003	B2
6643530	Diab et al.	Nov 2003	B2
6650917	Diab et al.	Nov 2003	B2
6654624	Diab et al.	Nov 2003	B2
6658276	Kiani et al.	Dec 2003	B2
6661161	Lanzo et al.	Dec 2003	B1
6671531	Al-Ali et al.	Dec 2003	B2
6678543	Diab et al.	Jan 2004	B2
6684090	Ali et al.	Jan 2004	B2
6684091	Parker	Jan 2004	B2
6697164	Babayoff	Feb 2004	B1
6697656	Al-Ali	Feb 2004	B1
6697657	Shehada et al.	Feb 2004	B1
6697658	Al-Ali	Feb 2004	B2
RE38476	Diab et al.	Mar 2004	E
6699194	Diab et al.	Mar 2004	B1
6714804	Al-Ali et al.	Mar 2004	B2
RE38492	Diab et al.	Apr 2004	E
6721582	Trepagnier et al.	Apr 2004	B2
6721585	Parker	Apr 2004	B1
6725075	Al-Ali	Apr 2004	B2
6728560	Kollias et al.	Apr 2004	B2
6735459	Parker	May 2004	B2
6745060	Diab et al.	Jun 2004	B2
6760607	Al-Ali	Jul 2004	B2
6770028	Ali et al.	Aug 2004	B1
6771994	Kiani et al.	Aug 2004	B2
6792300	Diab et al.	Sep 2004	B1
6801803	Viertio-Oja	Oct 2004	B2
6813511	Diab et al.	Nov 2004	B2
6816741	Diab	Nov 2004	B2
6822564	Al-Ali	Nov 2004	B2
6826419	Diab et al.	Nov 2004	B2
6830711	Mills et al.	Dec 2004	B2
6850787	Weber et al.	Feb 2005	B2
6850788	Al-Ali	Feb 2005	B2
6852083	Caro et al.	Feb 2005	B2
6861639	Al-Ali	Mar 2005	B2
6898452	Al-Ali et al.	May 2005	B2
6920345	Al-Ali et al.	Jul 2005	B2
6931268	Kiani-Azarbayjany et al.	Aug 2005	B1
6934570	Kiani et al.	Aug 2005	B2
6939305	Flaherty et al.	Sep 2005	B2
6943348	Coffin, IV	Sep 2005	B1
6944501	Pless	Sep 2005	B1
6950687	Al-Ali	Sep 2005	B2
6961598	Diab	Nov 2005	B2
6970792	Diab	Nov 2005	B1
6979812	Al-Ali	Dec 2005	B2
6985764	Mason et al.	Jan 2006	B2
6993371	Kiani et al.	Jan 2006	B2
6996427	Ali et al.	Feb 2006	B2
6999904	Weber et al.	Feb 2006	B2
7003338	Weber et al.	Feb 2006	B2
7003339	Diab et al.	Feb 2006	B2
7015451	Dalke et al.	Mar 2006	B2
7024233	Ali et al.	Apr 2006	B2
7027849	Al-Ali	Apr 2006	B2
7030749	Al-Ali	Apr 2006	B2
7039449	Al-Ali	May 2006	B2
7041060	Flaherty et al.	May 2006	B2
7044918	Diab	May 2006	B2
7048687	Reuss et al.	May 2006	B1
7067893	Mills et al.	Jun 2006	B2
7096052	Mason et al.	Aug 2006	B2
7096054	Abdul-Hafiz et al.	Aug 2006	B2
7132641	Schulz et al.	Nov 2006	B2
7142901	Kiani et al.	Nov 2006	B2
7149561	Diab	Dec 2006	B2
7186966	Al-Ali	Mar 2007	B2
7190261	Al-Ali	Mar 2007	B2
7215984	Diab	May 2007	B2
7215986	Diab	May 2007	B2
7221971	Diab	May 2007	B2
7225006	Al-Ali et al.	May 2007	B2
7225007	Al-Ali	May 2007	B2
RE39672	Shehada et al.	Jun 2007	E
7239905	Kiani-Azarbayjany et al.	Jul 2007	B2
7245953	Parker	Jul 2007	B1
7254429	Schurman et al.	Aug 2007	B2
7254431	Al-Ali	Aug 2007	B2
7254433	Diab et al.	Aug 2007	B2
7254434	Schulz et al.	Aug 2007	B2
7272425	Al-Ali	Sep 2007	B2
7274955	Kiani et al.	Sep 2007	B2
D554263	Al-Ali	Oct 2007	S
7280550	Rosenboom	Oct 2007	B1
7280858	Al-Ali et al.	Oct 2007	B2
7289835	Mansfield et al.	Oct 2007	B2
7292883	De Felice et al.	Nov 2007	B2
7295866	Al-Ali	Nov 2007	B2
7308894	Hickle	Dec 2007	B2
7328053	Diab et al.	Feb 2008	B1
7332784	Mills et al.	Feb 2008	B2
7340287	Mason et al.	Mar 2008	B2
7341559	Schulz et al.	Mar 2008	B2
7343186	Lamego et al.	Mar 2008	B2
D566282	Al-Ali et al.	Apr 2008	S
7355512	Al-Ali	Apr 2008	B1
7356365	Schurman	Apr 2008	B2
7371981	Abdul-Hafiz	May 2008	B2
7373193	Al-Ali et al.	May 2008	B2
7373194	Weber et al.	May 2008	B2
7376453	Diab et al.	May 2008	B1
7377794	Al Ali et al.	May 2008	B2
7377899	Weber et al.	May 2008	B2
7383070	Diab et al.	Jun 2008	B2
7407485	Huiku	Aug 2008	B2
7415297	Al-Ali et al.	Aug 2008	B2
7428432	Ali et al.	Sep 2008	B2
7438683	Al-Ali et al.	Oct 2008	B2
7440787	Diab	Oct 2008	B2
7454240	Diab et al.	Nov 2008	B2
7467002	Weber et al.	Dec 2008	B2
7469157	Diab et al.	Dec 2008	B2
7471969	Diab et al.	Dec 2008	B2
7471971	Diab et al.	Dec 2008	B2
7483729	Al-Ali et al.	Jan 2009	B2
7483730	Diab et al.	Jan 2009	B2
7489958	Diab et al.	Feb 2009	B2
7496391	Diab et al.	Feb 2009	B2
7496393	Diab et al.	Feb 2009	B2
D587657	Al-Ali et al.	Mar 2009	S
7499741	Diab et al.	Mar 2009	B2
7499835	Weber et al.	Mar 2009	B2
7500950	Al-Ali et al.	Mar 2009	B2
7509154	Diab et al.	Mar 2009	B2
7509494	Al-Ali	Mar 2009	B2
7510849	Schurman et al.	Mar 2009	B2
7526328	Diab et al.	Apr 2009	B2
7530942	Diab	May 2009	B1
7530949	Al Ali et al.	May 2009	B2
7530955	Diab et al.	May 2009	B2
7563110	Al-Ali et al.	Jul 2009	B2
7596398	Al-Ali et al.	Sep 2009	B2
7618375	Flaherty	Nov 2009	B2
D606659	Kiani et al.	Dec 2009	S
7647083	Al-Ali et al.	Jan 2010	B2
D609193	Al-Ali et al.	Feb 2010	S
D614305	Al-Ali et al.	Apr 2010	S
RE41317	Parker	May 2010	E
7725173	Viertio-Oja	May 2010	B2
7729733	Al-Ali et al.	Jun 2010	B2
7734320	Al-Ali	Jun 2010	B2
7761127	Al-Ali et al.	Jul 2010	B2
7761128	Al-Ali et al.	Jul 2010	B2
7761146	Carlson	Jul 2010	B2
7764982	Dalke et al.	Jul 2010	B2
D621516	Kiani et al.	Aug 2010	S
7791155	Diab	Sep 2010	B2
7801581	Diab	Sep 2010	B2
7822452	Schurman et al.	Oct 2010	B2
RE41912	Parker	Nov 2010	E
7844313	Kiani et al.	Nov 2010	B2
7844314	Al-Ali	Nov 2010	B2
7844315	Al-Ali	Nov 2010	B2
7865222	Weber et al.	Jan 2011	B2
7873497	Weber et al.	Jan 2011	B2
7880606	Al-Ali	Feb 2011	B2
7880626	Al-Ali et al.	Feb 2011	B2
7891355	Al-Ali et al.	Feb 2011	B2
7894868	Al-Ali et al.	Feb 2011	B2
7899507	Al-Ali et al.	Mar 2011	B2
7899518	Trepagnier et al.	Mar 2011	B2
7904132	Weber et al.	Mar 2011	B2
7909772	Popov et al.	Mar 2011	B2
7910875	Al-Ali	Mar 2011	B2
7917199	Drew	Mar 2011	B2
7919713	Al-Ali et al.	Apr 2011	B2
7925338	Huiku	Apr 2011	B2
7937128	Al-Ali	May 2011	B2
7937129	Mason et al.	May 2011	B2
7937130	Diab et al.	May 2011	B2
7941199	Kiani	May 2011	B2
7951086	Flaherty et al.	May 2011	B2
7957780	Lamego et al.	Jun 2011	B2
7962188	Kiani et al.	Jun 2011	B2
7962190	Diab et al.	Jun 2011	B1
7976472	Kiani	Jul 2011	B2
7988637	Diab	Aug 2011	B2
7990382	Kiani	Aug 2011	B2
7991446	Al-Ali et al.	Aug 2011	B2
8000761	Al-Ali	Aug 2011	B2
8008088	Bellott et al.	Aug 2011	B2
RE42753	Kiani-Azarbayjany et al.	Sep 2011	E
8019400	Diab et al.	Sep 2011	B2
8028701	Al-Ali et al.	Oct 2011	B2
8029765	Bellott et al.	Oct 2011	B2
8036727	Schurman et al.	Oct 2011	B2
8036728	Diab et al.	Oct 2011	B2
8046040	Ali et al.	Oct 2011	B2
8046041	Diab et al.	Oct 2011	B2
8046042	Diab et al.	Oct 2011	B2
8048040	Kiani	Nov 2011	B2
8050728	Al-Ali et al.	Nov 2011	B2
RE43169	Parker	Feb 2012	E
8118620	Al-Ali et al.	Feb 2012	B2
8126528	Diab et al.	Feb 2012	B2
8128572	Diab et al.	Mar 2012	B2
8130105	Al-Ali et al.	Mar 2012	B2
8145287	Diab et al.	Mar 2012	B2
8150487	Diab et al.	Apr 2012	B2
8175672	Parker	May 2012	B2
8180420	Diab et al.	May 2012	B2
8182443	Kiani	May 2012	B1
8185180	Diab et al.	May 2012	B2
8190223	Al-Ali et al.	May 2012	B2
8190227	Diab et al.	May 2012	B2
8203438	Kiani et al.	Jun 2012	B2
8203704	Merritt et al.	Jun 2012	B2
8204566	Schurman et al.	Jun 2012	B2
8219172	Schurman et al.	Jul 2012	B2
8219187	Sarkela	Jul 2012	B2
8224411	Al-Ali et al.	Jul 2012	B2
8228181	Al-Ali	Jul 2012	B2
8229533	Diab et al.	Jul 2012	B2
8233955	Al-Ali et al.	Jul 2012	B2
8244325	Al-Ali et al.	Aug 2012	B2
8255026	Al-Ali	Aug 2012	B1
8255027	Al-Ali et al.	Aug 2012	B2
8255028	Al-Ali et al.	Aug 2012	B2
8260577	Weber et al.	Sep 2012	B2
8265723	McHale et al.	Sep 2012	B1
8274360	Sampath et al.	Sep 2012	B2
8280473	Al-Ali	Oct 2012	B2
8301217	Al-Ali et al.	Oct 2012	B2
8306596	Schurman et al.	Nov 2012	B2
8310336	Muhsin et al.	Nov 2012	B2
8315683	Al-Ali et al.	Nov 2012	B2
RE43860	Parker	Dec 2012	E
8337403	Al-Ali et al.	Dec 2012	B2
8346330	Lamego	Jan 2013	B2
8353842	Al-Ali et al.	Jan 2013	B2
8355766	MacNeish, III et al.	Jan 2013	B2
8359080	Diab et al.	Jan 2013	B2
8364223	Al-Ali et al.	Jan 2013	B2
8364226	Diab et al.	Jan 2013	B2
8374665	Lamego	Feb 2013	B2
8385995	Al-ali et al.	Feb 2013	B2
8385996	Smith et al.	Feb 2013	B2
8388353	Kiani et al.	Mar 2013	B2
8399822	Al-Ali	Mar 2013	B2
8401602	Kiani	Mar 2013	B2
8405608	Al-Ali et al.	Mar 2013	B2
8414499	Al-Ali et al.	Apr 2013	B2
8418524	Al-Ali	Apr 2013	B2
8423106	Lamego et al.	Apr 2013	B2
8428967	Olsen et al.	Apr 2013	B2
8430817	Al-Ali et al.	Apr 2013	B1
8437825	Dalvi et al.	May 2013	B2
8455290	Siskavich	Jun 2013	B2
8457703	Al-Ali	Jun 2013	B2
8457707	Kiani	Jun 2013	B2
8463349	Diab et al.	Jun 2013	B2
8466286	Bellot et al.	Jun 2013	B2
8471713	Poeze et al.	Jun 2013	B2
8473020	Kiani et al.	Jun 2013	B2
8483787	Al-Ali et al.	Jul 2013	B2
8489364	Weber et al.	Jul 2013	B2
8498684	Weber et al.	Jul 2013	B2
8504128	Blank et al.	Aug 2013	B2
8509867	Workman et al.	Aug 2013	B2
8515509	Bruinsma et al.	Aug 2013	B2
8523781	Al-Ali	Sep 2013	B2
8529301	Al-Ali et al.	Sep 2013	B2
8532727	Ali et al.	Sep 2013	B2
8532728	Diab et al.	Sep 2013	B2
D692145	Al-Ali et al.	Oct 2013	S
8547209	Kiani et al.	Oct 2013	B2
8548548	Al-Ali	Oct 2013	B2
8548549	Schurman et al.	Oct 2013	B2
8548550	Al-Ali et al.	Oct 2013	B2
8560032	Al-Ali et al.	Oct 2013	B2
8560034	Diab et al.	Oct 2013	B1
8570167	Al-Ali	Oct 2013	B2
8570503	Vo et al.	Oct 2013	B2
8571617	Reichgott et al.	Oct 2013	B2
8571618	Lamego et al.	Oct 2013	B1
8571619	Al-Ali et al.	Oct 2013	B2
8577431	Lamego et al.	Nov 2013	B2
8581732	Al-Ali et al.	Nov 2013	B2
8584345	Al-Ali et al.	Nov 2013	B2
8588880	Abdul-Hafiz et al.	Nov 2013	B2
8600467	Al-Ali et al.	Dec 2013	B2
8606342	Diab	Dec 2013	B2
8626255	Al-Ali et al.	Jan 2014	B2
8630691	Lamego et al.	Jan 2014	B2
8634889	Al-Ali et al.	Jan 2014	B2
8641631	Sierra et al.	Feb 2014	B2
8652060	Al-Ali	Feb 2014	B2
8663107	Kiani	Mar 2014	B2
8666468	Al-Ali	Mar 2014	B1
8667967	Al- Ali et al.	Mar 2014	B2
8670811	O'Reilly	Mar 2014	B2
8670814	Diab et al.	Mar 2014	B2
8676286	Weber et al.	Mar 2014	B2
8682407	Al-Ali	Mar 2014	B2
RE44823	Parker	Apr 2014	E
RE44875	Kiani et al.	Apr 2014	E
8690799	Telfort et al.	Apr 2014	B2
8700112	Kiani	Apr 2014	B2
8702627	Telfort et al.	Apr 2014	B2
8706179	Parker	Apr 2014	B2
8712494	MacNeish, III et al.	Apr 2014	B1
8715206	Telfort et al.	May 2014	B2
8718735	Lamego et al.	May 2014	B2
8718737	Diab et al.	May 2014	B2
8718738	Blank et al.	May 2014	B2
8720249	Al-Ali	May 2014	B2
8721541	Al-Ali et al.	May 2014	B2
8721542	Al-Ali et al.	May 2014	B2
8723677	Kiani	May 2014	B1
8740792	Kiani et al.	Jun 2014	B1
8754776	Poeze et al.	Jun 2014	B2
8755535	Telfort et al.	Jun 2014	B2
8755856	Diab et al.	Jun 2014	B2
8755872	Marinow	Jun 2014	B1
8761850	Lamego	Jun 2014	B2
8764671	Kiani	Jul 2014	B2
8768423	Shakespeare et al.	Jul 2014	B2
8771204	Telfort et al.	Jul 2014	B2
8777634	Kiani et al.	Jul 2014	B2
8781543	Diab et al.	Jul 2014	B2
8781544	Al-Ali et al.	Jul 2014	B2
8781549	Al-Ali et al.	Jul 2014	B2
8788003	Schurman et al.	Jul 2014	B2
8790268	Al-Ali	Jul 2014	B2
8801613	Al-Ali et al.	Aug 2014	B2
8821397	Al-Ali et al.	Sep 2014	B2
8821415	Al-Ali et al.	Sep 2014	B2
8830449	Lamego et al.	Sep 2014	B1
8831700	Schurman et al.	Sep 2014	B2
8840549	Al-Ali et al.	Sep 2014	B2
8847740	Kiani et al.	Sep 2014	B2
8849365	Smith et al.	Sep 2014	B2
8852094	Al-Ali et al.	Oct 2014	B2
8852994	Wojtczuk et al.	Oct 2014	B2
8868147	Stippick et al.	Oct 2014	B2
8868150	Al-Ali et al.	Oct 2014	B2
8870792	Al-Ali et al.	Oct 2014	B2
8886271	Kiani et al.	Nov 2014	B2
8888539	Al-Ali et al.	Nov 2014	B2
8888708	Diab et al.	Nov 2014	B2
8892180	Weber et al.	Nov 2014	B2
8897847	Al-Ali	Nov 2014	B2
8909310	Lamego et al.	Dec 2014	B2
8911377	Al-Ali	Dec 2014	B2
8912909	Al-Ali et al.	Dec 2014	B2
8920317	Al-Ali et al.	Dec 2014	B2
8921699	Al-Ali et al.	Dec 2014	B2
8922382	Al-Ali et al.	Dec 2014	B2
8929964	Al-Ali et al.	Jan 2015	B2
8942777	Diab et al.	Jan 2015	B2
8948834	Diab et al.	Feb 2015	B2
8948835	Diab	Feb 2015	B2
8965471	Lamego	Feb 2015	B2
8983564	Al-Ali	Mar 2015	B2
8989831	Al-Ali et al.	Mar 2015	B2
8996085	Kiani et al.	Mar 2015	B2
8998809	Kiani	Apr 2015	B2
9028429	Telfort et al.	May 2015	B2
9037207	Al-Ali et al.	May 2015	B2
9060721	Reichgott et al.	Jun 2015	B2
9066666	Kiani	Jun 2015	B2
9066680	Al-Ali et al.	Jun 2015	B1
9072474	Al-Ali et al.	Jul 2015	B2
9078560	Schurman et al.	Jul 2015	B2
9084569	Weber et al.	Jul 2015	B2
9095316	Welch et al.	Aug 2015	B2
9106038	Telfort et al.	Aug 2015	B2
9107625	Telfort et al.	Aug 2015	B2
9107626	Al-Ali et al.	Aug 2015	B2
9113831	Al-Ali	Aug 2015	B2
9113832	Al-Ali	Aug 2015	B2
9119595	Lamego	Sep 2015	B2
9131881	Diab et al.	Sep 2015	B2
9131882	Al-Ali et al.	Sep 2015	B2
9131883	Al-Ali	Sep 2015	B2
9131917	Telfort et al.	Sep 2015	B2
9138180	Coverston et al.	Sep 2015	B1
9138182	Al-Ali et al.	Sep 2015	B2
9138192	Weber et al.	Sep 2015	B2
9142117	Muhsin et al.	Sep 2015	B2
9153112	Kiani et al.	Oct 2015	B1
9153121	Kiani et al.	Oct 2015	B2
9161696	Al-Ali et al.	Oct 2015	B2
9161713	Al-Ali et al.	Oct 2015	B2
9167995	Lamego et al.	Oct 2015	B2
9176141	Al-Ali et al.	Nov 2015	B2
9186102	Bruinsma et al.	Nov 2015	B2
9192312	Al-Ali	Nov 2015	B2
9192329	Al-Ali	Nov 2015	B2
9192330	Lin	Nov 2015	B2
9192351	Telfort et al.	Nov 2015	B1
9195385	Al-Ali et al.	Nov 2015	B2
9211072	Kiani	Dec 2015	B2
9211095	Al-Ali	Dec 2015	B1
9218454	Kiani et al.	Dec 2015	B2
9226696	Kiani	Jan 2016	B2
9241662	Al-Ali et al.	Jan 2016	B2
9245668	Vo et al.	Jan 2016	B1
9259185	Abdul-Hafiz et al.	Feb 2016	B2
9267572	Barker et al.	Feb 2016	B2
9277880	Poeze et al.	Mar 2016	B2
9289167	Diab et al.	Mar 2016	B2
9295421	Kiani et al.	Mar 2016	B2
9307928	Al-Ali et al.	Apr 2016	B1
9323894	Kiani	Apr 2016	B2
D755392	Hwang et al.	May 2016	S
9326712	Kiani	May 2016	B1
9333316	Kiani	May 2016	B2
9339220	Lamego et al.	May 2016	B2
9341565	Lamego et al.	May 2016	B2
9351673	Diab et al.	May 2016	B2
9351675	Al-Ali et al.	May 2016	B2
9364181	Kiani et al.	Jun 2016	B2
9368671	Wojtczuk et al.	Jun 2016	B2
9370325	Al-Ali et al.	Jun 2016	B2
9370326	McHale et al.	Jun 2016	B2
9370335	Al-ali et al.	Jun 2016	B2
9375185	Ali et al.	Jun 2016	B2
9386953	Al-Ali	Jul 2016	B2
9386961	Al-Ali et al.	Jul 2016	B2
9392945	Al-Ali et al.	Jul 2016	B2
9397448	Al-Ali et al.	Jul 2016	B2
9408542	Kinast et al.	Aug 2016	B1
9436645	Al-Ali et al.	Sep 2016	B2
9445759	Lamego et al.	Sep 2016	B1
9466919	Kiani et al.	Oct 2016	B2
9474474	Lamego et al.	Oct 2016	B2
9480422	Al-Ali	Nov 2016	B2
9480435	Olsen	Nov 2016	B2
9492110	Al-Ali et al.	Nov 2016	B2
9510779	Poeze et al.	Dec 2016	B2
9517024	Kiani et al.	Dec 2016	B2
9532722	Lamego et al.	Jan 2017	B2
9538949	Al-Ali et al.	Jan 2017	B2
9538980	Telfort et al.	Jan 2017	B2
9549696	Lamego et al.	Jan 2017	B2
9554737	Schurman et al.	Jan 2017	B2
9560996	Kiani	Feb 2017	B2
9560998	Al-Ali et al.	Feb 2017	B2
9566019	Al-Ali et al.	Feb 2017	B2
9579039	Jansen et al.	Feb 2017	B2
9591975	Dalvi et al.	Mar 2017	B2
9622692	Lamego et al.	Apr 2017	B2
9622693	Diab	Apr 2017	B2
D788312	Al-Ali et al.	May 2017	S
9636055	Al-Ali et al.	May 2017	B2
9636056	Al-Ali	May 2017	B2
9649054	Lamego et al.	May 2017	B2
9662052	Al-Ali et al.	May 2017	B2
9668679	Schurman et al.	Jun 2017	B2
9668680	Bruinsma et al.	Jun 2017	B2
9668703	Al-Ali	Jun 2017	B2
9675286	Diab	Jun 2017	B2
9687160	Kiani	Jun 2017	B2
9693719	Al-Ali et al.	Jul 2017	B2
9693737	Al-Ali	Jul 2017	B2
9697928	Al-Ali et al.	Jul 2017	B2
9712318	Foerster	Jul 2017	B2
9717425	Kiani et al.	Aug 2017	B2
9717458	Lamego et al.	Aug 2017	B2
9724016	Al-Ali et al.	Aug 2017	B1
9724024	Al-Ali	Aug 2017	B2
9724025	Kiani et al.	Aug 2017	B1
9730640	Diab et al.	Aug 2017	B2
9743887	Al-Ali et al.	Aug 2017	B2
9749232	Sampath et al.	Aug 2017	B2
9750442	Olsen	Sep 2017	B2
9750443	Smith et al.	Sep 2017	B2
9750461	Telfort	Sep 2017	B1
9775545	Al-Ali et al.	Oct 2017	B2
9775546	Diab et al.	Oct 2017	B2
9775570	Al-Ali	Oct 2017	B2
9778079	Al-Ali et al.	Oct 2017	B1
9782077	Lamego et al.	Oct 2017	B2
9782110	Kiani	Oct 2017	B2
9787568	Lamego et al.	Oct 2017	B2
9788735	Al-Ali	Oct 2017	B2
9788768	Al-Ali et al.	Oct 2017	B2
9795300	Al-Ali	Oct 2017	B2
9795310	Al-Ali	Oct 2017	B2
9795358	Telfort et al.	Oct 2017	B2
9795739	Al-Ali et al.	Oct 2017	B2
9801556	Kiani	Oct 2017	B2
9801588	Weber et al.	Oct 2017	B2
9808188	Perea et al.	Nov 2017	B1
9814418	Weber et al.	Nov 2017	B2
9820691	Kiani	Nov 2017	B2
9833152	Kiani et al.	Dec 2017	B2
9833180	Shakespeare et al.	Dec 2017	B2
9839379	Al-Ali et al.	Dec 2017	B2
9839381	Weber et al.	Dec 2017	B1
9847002	Kiani et al.	Dec 2017	B2
9847749	Kiani et al.	Dec 2017	B2
9848800	Lee et al.	Dec 2017	B1
9848806	Al-Ali et al.	Dec 2017	B2
9848807	Lamego	Dec 2017	B2
9861298	Eckerbom et al.	Jan 2018	B2
9861304	Al-Ali et al.	Jan 2018	B2
9861305	Weber et al.	Jan 2018	B1
9867578	Al-Ali et al.	Jan 2018	B2
9872623	Al-Ali	Jan 2018	B2
9876320	Coverston et al.	Jan 2018	B2
9877650	Muhsin et al.	Jan 2018	B2
9877686	Al-Ali et al.	Jan 2018	B2
9891079	Dalvi	Feb 2018	B2
9895107	Al-Ali et al.	Feb 2018	B2
9913617	Al-Ali et al.	Mar 2018	B2
9924893	Schurman et al.	Mar 2018	B2
9924897	Abdul-Hafiz	Mar 2018	B1
9936917	Poeze et al.	Apr 2018	B2
9943269	Muhsin et al.	Apr 2018	B2
9949676	Al-Ali	Apr 2018	B2
9955937	Telfort	May 2018	B2
9965946	Al-Ali	May 2018	B2
9980667	Kiani et al.	May 2018	B2
D820865	Muhsin et al.	Jun 2018	S
9986919	Lamego et al.	Jun 2018	B2
9986952	Dalvi et al.	Jun 2018	B2
9989560	Poeze et al.	Jun 2018	B2
9993207	Al-Ali et al.	Jun 2018	B2
10007758	Al-Ali et al.	Jun 2018	B2
D822215	Al-Ali et al.	Jul 2018	S
D822216	Barker et al.	Jul 2018	S
10010276	Al-Ali et al.	Jul 2018	B2
10032002	Kiani et al.	Jul 2018	B2
10039482	Al-Ali et al.	Aug 2018	B2
10052037	Kinast et al.	Aug 2018	B2
10058275	Al-Ali et al.	Aug 2018	B2
10064562	Al-Ali	Sep 2018	B2
10086138	Novak, Jr.	Oct 2018	B1
10092200	Al-Ali et al.	Oct 2018	B2
10092249	Kiani et al.	Oct 2018	B2
10098550	Al-Ali et al.	Oct 2018	B2
10098591	Al-Ali et al.	Oct 2018	B2
10098610	Al-Ali et al.	Oct 2018	B2
D833624	DeJong et al.	Nov 2018	S
10123726	Al-Ali et al.	Nov 2018	B2
10130289	Al-Ali et al.	Nov 2018	B2
10130291	Schurman et al.	Nov 2018	B2
D835282	Barker et al.	Dec 2018	S
D835283	Barker et al.	Dec 2018	S
D835284	Barker et al.	Dec 2018	S
D835285	Barker et al.	Dec 2018	S
10149616	Al-Ali et al.	Dec 2018	B2
10154815	Al-Ali et al.	Dec 2018	B2
10159412	Lamego et al.	Dec 2018	B2
10188296	Al-Ali et al.	Jan 2019	B2
10188331	Al-Ali et al.	Jan 2019	B1
10188348	Kiani et al.	Jan 2019	B2
RE47218	Ali-Ali	Feb 2019	E
RE47244	Kiani et al.	Feb 2019	E
RE47249	Kiani et al.	Feb 2019	E
10194847	Al-Ali	Feb 2019	B2
10194848	Kiani et al.	Feb 2019	B1
10201298	Al-Ali et al.	Feb 2019	B2
10205272	Kiani et al.	Feb 2019	B2
10205291	Scruggs et al.	Feb 2019	B2
10213108	Al-Ali	Feb 2019	B2
10219706	Al-Ali	Mar 2019	B2
10219746	McHale et al.	Mar 2019	B2
10226187	Al-Ali et al.	Mar 2019	B2
10226576	Kiani	Mar 2019	B2
10231657	Al-Ali et al.	Mar 2019	B2
10231670	Blank et al.	Mar 2019	B2
10231676	Al-Ali et al.	Mar 2019	B2
RE47353	Kiani et al.	Apr 2019	E
10251585	Al-Ali et al.	Apr 2019	B2
10251586	Lamego	Apr 2019	B2
10255994	Sampath et al.	Apr 2019	B2
10258265	Poeze et al.	Apr 2019	B1
10258266	Poeze et al.	Apr 2019	B1
10271748	Al-Ali	Apr 2019	B2
10278626	Schurman et al.	May 2019	B2
10278648	Al-Ali et al.	May 2019	B2
10279247	Kiani	May 2019	B2
10292628	Poeze et al.	May 2019	B1
10292657	Abdul-Hafiz et al.	May 2019	B2
10292664	Al-Ali	May 2019	B2
10299708	Poeze et al.	May 2019	B1
10299709	Perea et al.	May 2019	B2
10305775	Lamego et al.	May 2019	B2
10307111	Muhsin et al.	Jun 2019	B2
10325681	Sampath et al.	Jun 2019	B2
10327337	Triman et al.	Jun 2019	B2
20040038169	Mandelkern	Feb 2004	A1
20050010166	Hickle	Jan 2005	A1
20050070812	Donofrio	Mar 2005	A1
20060161054	Reuss et al.	Jul 2006	A1
20070010755	Sarkela	Jan 2007	A1
20070010756	Viertio-Oja	Jan 2007	A1
20070010795	Sarkela	Jan 2007	A1
20070208322	Rantala	Sep 2007	A1
20070282478	Al-Ali et al.	Dec 2007	A1
20080243021	Causevic	Oct 2008	A1
20090131762	Pelzek	May 2009	A1
20090160642	Kim	Jun 2009	A1
20090247984	Lamego et al.	Oct 2009	A1
20090275813	Davis	Nov 2009	A1
20090275844	Al-Ali	Nov 2009	A1
20100004518	Vo et al.	Jan 2010	A1
20100030040	Poeze et al.	Feb 2010	A1
20100324441	Hargrove	Dec 2010	A1
20110054272	Derchak	Mar 2011	A1
20110082711	Poeze et al.	Apr 2011	A1
20110125060	Telfort et al.	May 2011	A1
20110172554	Leyde	Jul 2011	A1
20110184307	Hulin	Jul 2011	A1
20110208015	Welch et al.	Aug 2011	A1
20110230733	Al-Ali	Sep 2011	A1
20110270047	O'Brien	Nov 2011	A1
20120053433	Chamoun	Mar 2012	A1
20120083673	Al-Ali et al.	Apr 2012	A1
20120165629	Merritt et al.	Jun 2012	A1
20120203087	McKenna	Aug 2012	A1
20120209082	Al-Ali	Aug 2012	A1
20120209084	Olsen et al.	Aug 2012	A1
20120283524	Kiani et al.	Nov 2012	A1
20130023775	Lamego et al.	Jan 2013	A1
20130030267	Lisogurski	Jan 2013	A1
20130041591	Lamego	Feb 2013	A1
20130060147	Welch et al.	Mar 2013	A1
20130096405	Garfio	Apr 2013	A1
20130096936	Sampath et al.	Apr 2013	A1
20130150748	Jensen	Jun 2013	A1
20130243021	Siskavich	Sep 2013	A1
20130253334	Al-Ali et al.	Sep 2013	A1
20130276785	Melker	Oct 2013	A1
20130296672	O'Neil et al.	Nov 2013	A1
20130296713	Al-Ali et al.	Nov 2013	A1
20130324808	Al-Ali et al.	Dec 2013	A1
20130331660	Al-Ali et al.	Dec 2013	A1
20140012100	Al-Ali et al.	Jan 2014	A1
20140051953	Lamego et al.	Feb 2014	A1
20140120564	Workman et al.	May 2014	A1
20140121482	Merritt et al.	May 2014	A1
20140127137	Bellott et al.	May 2014	A1
20140163344	Al-Ali	Jun 2014	A1
20140166076	Kiani et al.	Jun 2014	A1
20140171763	Diab	Jun 2014	A1
20140180038	Kiani	Jun 2014	A1
20140180154	Sierra et al.	Jun 2014	A1
20140180160	Brown	Jun 2014	A1
20140187973	Brown et al.	Jul 2014	A1
20140213864	Abdul-Hafiz et al.	Jul 2014	A1
20140275835	Lamego et al.	Sep 2014	A1
20140275871	Lamego et al.	Sep 2014	A1
20140275872	Merritt et al.	Sep 2014	A1
20140288400	Diab et al.	Sep 2014	A1
20140316217	Purdon	Oct 2014	A1
20140316218	Purdon et al.	Oct 2014	A1
20140316228	Blank et al.	Oct 2014	A1
20140323825	Al-Ali et al.	Oct 2014	A1
20140323897	Brown et al.	Oct 2014	A1
20140323898	Purdon et al.	Oct 2014	A1
20140330092	Al-Ali et al.	Nov 2014	A1
20140330098	Merritt et al.	Nov 2014	A1
20140357966	Al-Ali et al.	Dec 2014	A1
20150005600	Blank et al.	Jan 2015	A1
20150011907	Purdon et al.	Jan 2015	A1
20150032029	Al-Ali et al.	Jan 2015	A1
20150038859	Dalvi et al.	Feb 2015	A1
20150080754	Purdon et al.	Mar 2015	A1
20150087936	Al-Ali et al.	Mar 2015	A1
20150094546	Al-Ali	Apr 2015	A1
20150099950	Al-Ali et al.	Apr 2015	A1
20150101844	Al-Ali et al.	Apr 2015	A1
20150106121	Muhsin et al.	Apr 2015	A1
20150112151	Muhsin et al.	Apr 2015	A1
20150142082	Simon	May 2015	A1
20150165312	Kiani	Jun 2015	A1
20150196249	Brown et al.	Jul 2015	A1
20150216459	Al-Ali et al.	Aug 2015	A1
20150238722	Al-Ali	Aug 2015	A1
20150245773	Lamego et al.	Sep 2015	A1
20150245794	Al-Ali	Sep 2015	A1
20150257689	Al-Ali et al.	Sep 2015	A1
20150272508	Chiouchang	Oct 2015	A1
20150272514	Kiani et al.	Oct 2015	A1
20150351697	Weber et al.	Dec 2015	A1
20150359429	Al-Ali et al.	Dec 2015	A1
20150366507	Blank	Dec 2015	A1
20160029932	Al-Ali	Feb 2016	A1
20160058347	Reichgott et al.	Mar 2016	A1
20160066824	Al-Ali et al.	Mar 2016	A1
20160081552	Wojtczuk et al.	Mar 2016	A1
20160095543	Telfort et al.	Apr 2016	A1
20160095548	Al-Ali et al.	Apr 2016	A1
20160103598	Al-Ali et al.	Apr 2016	A1
20160166182	Al-Ali et al.	Jun 2016	A1
20160166183	Poeze et al.	Jun 2016	A1
20160196388	Lamego	Jul 2016	A1
20160197436	Barker et al.	Jul 2016	A1
20160213281	Eckerbom et al.	Jul 2016	A1
20160228043	O'Neil et al.	Aug 2016	A1
20160233632	Scruggs et al.	Aug 2016	A1
20160234944	Schmidt et al.	Aug 2016	A1
20160270735	Diab et al.	Sep 2016	A1
20160283665	Sampath et al.	Sep 2016	A1
20160287090	Al-Ali et al.	Oct 2016	A1
20160287786	Kiani	Oct 2016	A1
20160296169	McHale et al.	Oct 2016	A1
20160310052	Al-Ali et al.	Oct 2016	A1
20160314260	Kiani	Oct 2016	A1
20160324488	Olsen	Nov 2016	A1
20160327984	Al-Ali et al.	Nov 2016	A1
20160331332	Al-Ali	Nov 2016	A1
20160367173	Dalvi et al.	Dec 2016	A1
20170000394	Al-Ali et al.	Jan 2017	A1
20170007134	Al-Ali et al.	Jan 2017	A1
20170007198	Al-Ali et al.	Jan 2017	A1
20170014083	Diab et al.	Jan 2017	A1
20170014084	Al-Ali et al.	Jan 2017	A1
20170024748	Haider	Jan 2017	A1
20170042488	Muhsin	Feb 2017	A1
20170055851	Al-Ali	Mar 2017	A1
20170055882	Al-Ali et al.	Mar 2017	A1
20170055887	Al-Ali	Mar 2017	A1
20170055896	Al-Ali et al.	Mar 2017	A1
20170079594	Telfort et al.	Mar 2017	A1
20170086723	Al-Ali et al.	Mar 2017	A1
20170143281	Olsen	May 2017	A1
20170147774	Kiani	May 2017	A1
20170156620	Al-Ali et al.	Jun 2017	A1
20170173632	Al-Ali	Jun 2017	A1
20170181693	Kim	Jun 2017	A1
20170187146	Kiani et al.	Jun 2017	A1
20170188919	Al-Ali et al.	Jul 2017	A1
20170196464	Jansen et al.	Jul 2017	A1
20170196470	Lamego et al.	Jul 2017	A1
20170224262	Al-Ali	Aug 2017	A1
20170228516	Sampath et al.	Aug 2017	A1
20170245790	Al-Ali et al.	Aug 2017	A1
20170251974	Shreim et al.	Sep 2017	A1
20170251975	Shreim et al.	Sep 2017	A1
20170258403	Abdul-Hafiz et al.	Sep 2017	A1
20170311851	Schurman et al.	Nov 2017	A1
20170311891	Kiani et al.	Nov 2017	A1
20170325728	Al-Ali et al.	Nov 2017	A1
20170332976	Al-Ali et al.	Nov 2017	A1
20170340293	Al-Ali et al.	Nov 2017	A1
20170360310	Kiani et al.	Dec 2017	A1
20170367632	Al-Ali et al.	Dec 2017	A1
20180008146	Al-Ali et al.	Jan 2018	A1
20180013562	Haider et al.	Jan 2018	A1
20180014752	Al-Ali et al.	Jan 2018	A1
20180028124	Al-Ali et al.	Feb 2018	A1
20180055385	Al-Ali	Mar 2018	A1
20180055390	Kiani et al.	Mar 2018	A1
20180055430	Diab et al.	Mar 2018	A1
20180064381	Shakespeare et al.	Mar 2018	A1
20180069776	Lamego et al.	Mar 2018	A1
20180070867	Smith et al.	Mar 2018	A1
20180082767	Al-Ali et al.	Mar 2018	A1
20180085068	Telfort	Mar 2018	A1
20180087937	Al-Ali et al.	Mar 2018	A1
20180103874	Lee et al.	Apr 2018	A1
20180103905	Kiani	Apr 2018	A1
20180110478	Al-Ali	Apr 2018	A1
20180116575	Perea et al.	May 2018	A1
20180125368	Lamego et al.	May 2018	A1
20180125430	Al-Ali et al.	May 2018	A1
20180125445	Telfort et al.	May 2018	A1
20180130325	Kiani et al.	May 2018	A1
20180132769	Weber et al.	May 2018	A1
20180132770	Lamego	May 2018	A1
20180146901	Al-Ali et al.	May 2018	A1
20180146902	Kiani et al.	May 2018	A1
20180153442	Eckerbom et al.	Jun 2018	A1
20180153446	Kiani	Jun 2018	A1
20180153447	Al-Ali et al.	Jun 2018	A1
20180153448	Weber et al.	Jun 2018	A1
20180161499	Al-Ali et al.	Jun 2018	A1
20180168491	Al-Ali et al.	Jun 2018	A1
20180174679	Sampath et al.	Jun 2018	A1
20180174680	Sampath et al.	Jun 2018	A1
20180182484	Sampath et al.	Jun 2018	A1
20180184917	Kiani	Jul 2018	A1
20180192924	Al-Ali	Jul 2018	A1
20180192953	Shreim et al.	Jul 2018	A1
20180192955	Al-Ali et al.	Jul 2018	A1
20180199871	Pauley et al.	Jul 2018	A1
20180206795	Al-Ali	Jul 2018	A1
20180206815	Telfort	Jul 2018	A1
20180213583	Al-Ali	Jul 2018	A1
20180214031	Kiani et al.	Aug 2018	A1
20180214090	Al-Ali et al.	Aug 2018	A1
20180218792	Muhsin et al.	Aug 2018	A1
20180225960	Al-Ali et al.	Aug 2018	A1
20180238718	Dalvi	Aug 2018	A1
20180242853	Al-Ali	Aug 2018	A1
20180242921	Muhsin et al.	Aug 2018	A1
20180242923	Al-Ali et al.	Aug 2018	A1
20180242924	Barker et al.	Aug 2018	A1
20180242926	Muhsin et al.	Aug 2018	A1
20180247353	Al-Ali et al.	Aug 2018	A1
20180247712	Muhsin et al.	Aug 2018	A1
20180249933	Schurman et al.	Sep 2018	A1
20180253947	Muhsin et al.	Sep 2018	A1
20180256087	Al-Ali et al.	Sep 2018	A1
20180256113	Weber et al.	Sep 2018	A1
20180285094	Housel et al.	Oct 2018	A1
20180289325	Poeze et al.	Oct 2018	A1
20180289337	Al-Ali et al.	Oct 2018	A1
20180296161	Shreim et al.	Oct 2018	A1
20180300919	Muhsin et al.	Oct 2018	A1
20180310822	Indorf et al.	Nov 2018	A1
20180310823	Al-Ali et al.	Nov 2018	A1
20180317826	Muhsin	Nov 2018	A1
20180317841	Novak, Jr.	Nov 2018	A1
20180333055	Lamego et al.	Nov 2018	A1
20180333087	Al-Ali	Nov 2018	A1
20190000317	Muhsin et al.	Jan 2019	A1
20190000362	Kiani et al.	Jan 2019	A1
20190015023	Monfre	Jan 2019	A1
20190021638	Al-Ali et al.	Jan 2019	A1
20190029574	Schurman et al.	Jan 2019	A1
20190029578	Al-Ali et al.	Jan 2019	A1
20190038143	Al-Ali	Feb 2019	A1
20190058280	Al-Ali et al.	Feb 2019	A1
20190058281	Al-Ali et al.	Feb 2019	A1
20190069813	Al-Ali	Mar 2019	A1
20190069814	Al-Ali	Mar 2019	A1
20190076028	Al-Ali et al.	Mar 2019	A1
20190082979	Al-Ali et al.	Mar 2019	A1
20190090748	Al-Ali	Mar 2019	A1
20190090760	Kinast et al.	Mar 2019	A1
20190090764	Al-Ali	Mar 2019	A1
20190104973	Poeze et al.	Apr 2019	A1
20190110719	Poeze et al.	Apr 2019	A1
20190117070	Muhsin et al.	Apr 2019	A1
20190117139	Al-Ali et al.	Apr 2019	A1
20190117140	Al-Ali et al.	Apr 2019	A1
20190117141	Al-Ali	Apr 2019	A1
20190117930	Al-Ali	Apr 2019	A1
20190122763	Sampath et al.	Apr 2019	A1
20190133525	Al-Ali et al.	May 2019	A1
20190142283	Lamego et al.	May 2019	A1
20190142344	Telfort et al.	May 2019	A1
20190150800	Poeze et al.	May 2019	A1
20190150856	Kiani et al.	May 2019	A1
20190167161	Al-Ali et al.	Jun 2019	A1
20190175019	Al-Ali et al.	Jun 2019	A1
20190192076	McHale et al.	Jun 2019	A1

Foreign Referenced Citations (2)

Number	Date	Country
1 741 388	Jan 2007	EP
WO 0232305	Apr 2002	WO

Non-Patent Literature Citations (1)

Entry
Ionescu, et al., C. M., Variable Time-Delay Estimation for Anesthesia Control During Intensive Care, IEEE Transactions on Biomedical Engineering, Feb. 1, 2011, pp. 363-369, vol. 58, No. 2, IEEE Service Center, Piscataway, NJ, USA.

Related Publications (1)

	Number	Date	Country
	20130331660 A1	Dec 2013	US

Provisional Applications (2)

	Number	Date	Country
	61703747	Sep 2012	US
	61656974	Jun 2012	US

Depth of consciousness monitor

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

CPC

International Classifications

Term Extension

Abstract